Targeting inhibition of the inflammatory response: advances in the treatment of myocardial fibrosis with natural medicine and active ingredients

Myocardial fibrosis is a critical pathological foundation of cardiovascular diseases and a fundamental process underlying myocardial remodeling. The inflammatory response is a key driver of myocardial fibrosis, promoting the proliferation of myocardial fibroblasts and collagen deposition through the activation of multiple cytokines and signaling pathways. Natural medicines and active ingredients exhibit distinct therapeutic advantages characterized by not only potent pharmacological efficacy and favorable safety profiles, but also unique multi-target mechanisms of action that enable synergistic modulation of complex pathological pathways. These properties enable them to comprehensively modulate the inflammatory response, thereby providing novel therapeutic strategies for myocardial fibrosis. In this review, we explore the etiology of myocardial fibrosis and the mechanisms by which natural medicines and active ingredients inhibit the inflammatory response to treat myocardial fibrosis. We aim to provide a solid reference for future research on natural medicine-based therapies targeting the inflammatory pathways involved in myocardial fibrosis.

1 Background

Cardiovascular disease (CVD) is a major global health problem and is currently the leading cause of death worldwide. In the United States, the prevalence of CVD is as high as 48.6% in adults over 20 years of age, and the prevalence increases with age (1). Myocardial fibrosis (MF) is one of the main manifestations of myocardial remodeling, which is often accompanied by atrial dilatation, cardiomyocyte hypertrophy, and cardiomyocyte apoptosis, and other cardiac manifestations, and has important pathophysiological significance in the development of CVD (2, 3). Myocardial fibrosis is characterized by abnormal proliferation of extracellular matrix fibroblasts, excessive collagen deposition and abnormal distribution (4), and its pathological process involves a variety of mechanisms such as inflammatory response, oxidative stress (OS), ferroptosis and mRNA. Among them, inflammatory response, as a key driver in the process of myocardial fibrosis, plays an important influence in the development of myocardial fibrosis.

The inflammatory response of the cardiovascular system is regulated by multiple systems including the immune response system, renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system, nitrosative redox homeostasis, calcium homeostasis, and heme oxygenase system. Systems that integrally regulate and interact with each other (5). The onset of inflammatory response leads to a large accumulation of inflammatory cells, some of which may release a large number of inflammatory factors, which may constitute an inflammatory pathway with other factors and act directly on fibroblasts, activating them into myofibroblasts and activating fibrotic macrophages and lymphocytes, which in turn triggers fibrotic programs in vascular cells and cardiomyocytes. In addition, long-term chronic inflammation may lead to necrosis of cardiomyocytes, triggering reparative fibrosis. However, the pleiotropic nature of inflammatory mediators and the heterogeneity of patients' cardiac remodeling pose a major challenge to the clinical implementation of strategies targeting the inflammatory response. Dissecting the molecular mechanisms by which inflammatory mediators and related signaling pathways regulate myocardial fibrosis is important for improving the survival and quality of life of patients with CVD (6).

Currently, modern medicine mainly adopts the strategy of inhibiting pro-fibrotic signaling in the treatment of myocardial fibrosis, with drugs such as angiotensin converting enzyme inhibitors (ACEIs) and β-blockers. Although these methods have been proved to have better clinical efficacy, they only have a single pathway of action and suffer from the disadvantages of high side effects and high treatment costs. Natural medicine and active ingredients have the characteristics of multi-component, multi-target and multi-level anti-fibrosis, which have their unique advantages for the treatment of different stages and types of myocardial fibrosis (7), and have good potential in the treatment of myocardial fibrosis. Based on the combing of the causes of myocardial fibrosis and the mechanism of inflammatory response and myocardial fibrosis, this review further composes and explores the process and mechanism of natural medicine and active ingredients regulating myocardial fibrosis by reducing the inflammatory response.

2 The cause of myocardial fibrosis

The causes of myocardial fibrosis are complex and varied. According to current research, they mainly include inflammation, oxidative stress, radiation factors, ferroptosis, myocardial electrical remodeling, microRNA and other factors, among which inflammation and oxidative stress are the most common. The complexity and variety of causes bring great challenges to clinical research as well as treatment. The following is an analysis and compilation of the causes of myocardial fibrosis.

2.1 Inflammatory response

Inflammatory response is a basic pathological process that occurs when biological tissues are subjected to certain stimuli, such as trauma, infection, etc., and is mainly a defense reaction. Inflammatory mediators are activated and induce myocardial fibrosis. This process mainly includes three steps: secretion of inflammatory cells and inflammatory factors after organ and tissue injury; activation of effector cells by inflammatory cells and inflammatory factors, which promotes proliferation and migration of effector cells; and further secretion of extracellular matrix (ECM) by effector cells, which contributes to myocardial remodeling (6). Inflammatory response-induced myocardial fibrosis is closely related to a variety of inflammatory cells, inflammatory factors and signaling pathways.

Inflammatory cells include mast cells, monocytes, lymphocytes, and macrophages. Mast cells can either directly promote the occurrence of myocardial fibrosis or accelerate the process of myocardial fibrosis through degranulation and release of inflammatory factors, fibrosis mediators, histamine, etc. M1 and M2 macrophages exhibit bidirectional regulation in myocardial fibrosis, which can accelerate myocardial fibrosis through pro-inflammatory response on one hand, and slow down the process of myocardial fibrosis through degradation of ECM on the other hand. Inflammatory factors include tumor necrosis factor (TNF), galectin-3 (gal-3), nuclear factor kappa-B (NF-κB) and interleukin (IL), which act on effector cells and promote myocardial fibrosis through multiple pathways. In addition, TGF-β/Smad signaling pathway, JAK2/STAT3 signaling pathway, and P38 MAPK signaling pathway also play important roles in myocardial fibrosis.

2.2 Oxidative stress

OS refers to a negative effect produced by free radicals in the body, which is manifested as an imbalance in which oxidative effects are stronger than antioxidative effects in the body (8). There are two sets of antioxidant systems in the body, enzymatic and non-enzymatic antioxidant systems, which lead to OS when they are not sufficient to reduce the oxidative state of the body (9). Organismal reactive oxygen species (ROS) are key substances that initiate, mediate, and regulate the OS process, and they participate in cellular signaling as signaling molecules under physiological conditions, as well as being an important contributor to organismal aging and the generation of disease (10). Studies have shown that OS is one of the major causes of myocardial fibrosis and interacts with other factors.

OS is associated with myocardial fibrosis through direct action as well as participation in cytokine signaling, which promotes the synthesis of pro-fibrotic cytokines, the activation of fibroblasts, and the accumulation of ECM (11). ROS directly regulate the quantity and quality of cardiac mesenchymal MMPs by regulating the expression and metabolism of matrix proteins. And an increase in OS activates MMP and reduces fibrillar collagen synthesis in cardiac fibroblasts (CFs) (12). In addition to its direct effects, ROS can enhance ECM deposition in the cardiac interstitium by activating transforming growth factor-β (TGF-β) (13). In addition, ROS are key mediators in the mechanism of both inflammatory factor and angiotensin II-induced fibroblast action (14). It plays an important role in the activation of mitogen-activated protein kinase (MAPK) and stress-responsive protein kinases by inflammatory factors. Thus, it promotes the activation of transcription factors such as activator protein-1 (AP-1), E-twenty six (Ets) transcription factor and NF-κB and enhances transcription of MMP (15). Meanwhile, angiotensin II activates downstream ROS-sensitive kinase, and this kinase also plays an important role in mediating the process of myocardial fibrosis (16) (Figure 1).

Figure 1

Figure 1. Oxidative stress and myocardial fibrosis. ROS directly regulate MMP in the cardiac interstitium and stimulate the proliferation of cardiac fibroblasts, which promotes the production of TGF-β and thus induces the development of myocardial fibrosis. ROS, after being stimulated by inflammatory factors, promote transcription factors, such as AP-1, ETS/NF-κB, through the activation of the p38 MAPK and SAPK/JNK pathways. activation and enhanced MMP transcription, thereby promoting myocardial fibrosis. Created in BioRender. Yan W (2025) https://BioRender.com/xf62e49.

2.3 Atrial electrical remodeling

Atrial electrical remodeling refers to changes in the electrophysiologic properties of the atrial muscle, triggered by recurrent episodes of atrial fibrillation (17). It has been pointed out that atrial electrical remodeling can be caused by a variety of factors, such as OS, inflammatory response, and abnormal gene expression, which can also lead to the formation of myocardial fibrosis (18). First, miR-21 expression was significantly elevated in patients with atrial fibrillation, and its expression was equally upregulated as an important factor in the process of myocardial fibrosis and inflammatory response (19). Secondly, inflammatory factors secreted by various inflammatory cells are increased during atrial fibrillation, which can not only cause changes in the expression and function of ion channels and further electrical remodeling of the atria, but also the inflammatory response, which is an important cause of myocardial fibrosis, will likewise have an impact (20). In addition, in the OS state, a large amount of ROS will disrupt ionic pathways and promote atrial electrical remodeling (21), and OS can also aggravate myocardial fibrosis. Overall, atrial electrical remodeling can indirectly affect myocardial fibrosis.

2.4 MicroRNA

MicroRNAs (miRNAs) are a class of endogenous, 19–24 nucleotide-long RNAs that were first identified in 1993 in Cryptobacterium hidradii nematodes (22). They function mainly through messenger RNAs, thereby affecting the expression of protein-coding genes (23). Increasingly, miRNAs have been shown to play an important role in the regulation of CVD, including myocardial fibrosis (24). miRNAs can be both pro- and anti-myocardial fibrosis, and whether they promote or inhibit depends on the type of miRNA (25).

MiR-21 and miR-133 mainly play a promotional role in myocardial fibrosis. MiR-21 is closely related to myocardial fibrosis and can affect myocardial fibrosis directly or indirectly from multiple targets. It has been suggested (26) that the three main target genes affecting myocardial fibrosis are SMAD family member 7 (Smad7) and sprouty1/2 (SPRY1/2), and miR-21 can promote myocardial fibrosis by controlling Smad7 and Spry1 (27, 28). In addition, overexpression of miR-21 induces myocardial fibrosis by regulating Jagged 1 and dual-specificity phosphatase 8 (DUSP8), and promotes the transformation of CFs to myofibroblasts and myocardial fibers by targeting Jagged1 (29). MiR-133 is expressed predominantly in cardiomyocytes and myocardial fibroblasts (30), and is involved in cardiomyocyte proliferation, differentiation, hypertrophy growth and other physiological activities, and is closely related to myocardial fibrosis (31).

MiR-29a, miR-30, miR-22, miR-34a, and miR-132 mainly exert inhibitory effects on myocardial fibrosis. MiR-29a, on the one hand, controls the mRNAs encoding the proteins involved in MF, and the overexpression of miR-29a directly leads to the reduction of such proteins (32). On the other hand, miR-29a overexpression inhibits the TGF-β pathway, leading to inhibition of myocardial fibrosis (33). MiR-30 is one of the most abundant miRNAs in the heart, which is released directly from the heart, and is closely related to the collagenvolume fraction (CVF) (34). MiR-30 restricts the key pro fibrotic protein connective tissue growth factor (CTGF) production and directly downregulates the key pro-fibrotic protein CTGF (35). Studies have shown (36) that overexpression of miR-30d improves cardiac function, reduces myocardial fibrosis, and decreases cardiomyocyte apoptosis in rat and mouse models of ischemic heart failure. MiR-22, a miRNA highly enriched in muscle, is also one of the most abundant cardiac miRNAs (37). In several experimental studies (38–41), miR-22 exhibited attenuation of myocardial fibrosis. MiR-34a is a non-negligible regulator in the process of myocardial fibrosis, and it has been experimentally demonstrated that miR-34a can inhibit myocardial fibrosis through multiple pathways (42–45). MiR-132, as a master regulator in the pathological process of heart failure, its role in the inhibition of myocardial fibrosis process, also showed an important role (46–48).

In summary, due to the numerous types of miRNAs and the diversity of their actions, they can affect myocardial fibrosis through various pathways, which also suggests that we can treat myocardial fibrosis-related diseases from multiple pathways (Figure 2).

Figure 2

Figure 2. MicroRNAs and myocardial fibrosis. MiR-21 promotes myocardial fibrosis by promoting the expression of Smad7, Spry1, and Jagged 1, and inhibiting the expression of DUSP8. miR-133 mainly activates the TGF-β/Smad pathway and TGF-RII for pro-fibrotic myocardial fibrosis. miR-29a inhibits myocardial fibrosis by inhibiting the expression of TGF-β, vascular endothelial Growth Factor A (VEGFA), and DNA methyltransferase 3A (DNMT3A) to inhibit myocardial fibrosis. miR-30 directly restricts CTGF production and inhibits TGF-β1. miR-22 mainly inhibits the PTEN/Akt/mTOR signalling pathway and directly down-regulates TGFBRI to exert an anti-fibrotic effect. miR-34a and miR-132 inhibit myocardial fibrosis mainly by inhibiting the TGF-β related pathway. Created in BioRender. Yan W (2025) https://BioRender.com/xf62e49.

2.5 Ferroptosis

Iron (Fe) is an essential micronutrient that carries a variety of physiological roles such as transportation and storage of oxygen, mitochondrial respiration and redox reactions (49). The human body contains about 2–5 g of total iron, most of which is bound intracellularly to heme or other non-heme proteins and enzymes in hemoglobin and myoglobin (50, 51). Extracellular iron accounts for only about 0.1% of the total body iron content, and most of which is bound to iron transferrin (TRF) in serum. Disturbances of iron homeostasis include iron overload and iron deficiency. Ferroptosis, an iron-dependent cell death driven by iron accumulation and lipid peroxidation, is characterized by glutathione depletion and inhibition of glutathione peroxidase 4 (GPX4), and has been implicated in the pathogenesis of several CVD (52). Various studies have demonstrated that ferroptosis mediated by iron metabolism imbalance, abnormal lipid peroxidation, reduced GPX4 activity, and inhibition of the cystine/glutamate transport system are closely associated with the development of tissue fibrosis (53, 54). It has now been demonstrated that ferroptosis occurs in ischemic cardiomyocytes and atrial myocytes from patients with atrial fibrillation (55).

Ferroptosis, as a novel type of regulated cell death, is widely involved in the onset and execution of cardiac fibrosis (56). The massive production of lipid ROS during ferroptosis promotes OS, leading to myocardial injury, death, and triggering cardiac fibrosis (57). In addition to promoting the fibrotic process by causing parenchymal cell death, ferroptosis can also promote myocardial fibrosis by inducing inflammation (58). After ferroptosis of cardiomyocyte, alarmins released by necrotic cells triggers a CFS phenotype of pro-inflammatory and matrix-degrading, which may contribute to leukocyte recruitment and activation of the TGF-β cascade response leading to the transformation of fibroblasts into myofibroblasts (59). Meanwhile, the expression of oxidative stress carbonyl protein markers and myocardial fibrosis (type III collagen) was increased in iron-overloaded type 1 diabetic rats (60), suggesting that the process of ferroptosis contributes to the process of myocardial fibrosis by increasing the production of myocardial collagen. Ferroptosis contributes to the development of metabolic diseases, which indirectly leads to increased fibrosis in myocardial tissue through mechanisms such as inflammatory response and OS (61). Furthermore, ferroptosis plays an important role in adriamycin-induced cardiomyopathy, which subsequently triggers myocardial fibrosis (62).

2.6 Radiation

Radiation is a specific factor in the induction of myocardial fibrosis. During radiation therapy for chest tumors, it is inevitable that some irradiation damage is caused to the heart, which in turn leads to a variety of serious complications such as myocardial fibrosis, pericardial disease, and damage to the cardiac conduction system. These are referred to as radiation-induced heart disease (RIHD). Radiation-induced myocardial fibrosis (RIMF) accounts for up to 80% of cases (63).

Although existing studies have not been able to clearly elucidate the mechanism of radiation-induced myocardial fibrosis, we know that it is a chronic process, and caused by the reciprocal interaction of multiple cytokines and pathways. Radiation first causes vascular injury and endothelial dysfunction, which play a key role in the development of RIMF because it leads to a proinflammatory and profibrotic environment (64–66). Subsequently, radiation can contribute to mitochondrial dysfunction (67) or contribute to the overproduction of ROS in vivo by inducing cardiomyocytes and endothelial cells to express high levels of NADPH oxidase 2 (NOX2) and NADPH oxidase 4 (NOX4), which leads to the development of OS (68). In addition, due to the damage of vascular and endothelial, a large number of leukocytes and neutrophils are recruited there, while secreting a large number of factors and inflammatory mediators to mediate the inflammatory response (69, 70). At the same time, miRNAs and the neuroimmune system are involved in the slow process of radiation-induced fibrosis (71, 72), which ultimately leads to the formation of myocardial fibrosis by interacting with other factors. In a sense, radiation, as the etiologic agent, induces the onset of a series of reactions in the body that lead to myocardial fibrosis, and then finally formed myocardial fibrosis (Figure 3).

Figure 3

Figure 3. Radiation and myocardial fibrosis. Radiation causes vascular damage and endothelial dysfunction, leading to large aggregations of leukocytes and neutrophils, which in turn secrete inflammatory factors and mediators to mediate the inflammatory response, creating a pro-inflammatory and pro-fibrotic environment. In addition, mitochondrial dysfunction and miRNAs are involved in the slow process of radiation-induced fibrosis, which, by interacting with other factors, leads to the formation of myocardial fibrosis. Created in BioRender. Li R (2025) https://BioRender.com/6beszmg.

3 Inflammatory response and myocardial fibrosis

3.1 Inflammatory cells and myocardial fibrosis

Inflammatory cells play a key role in the inflammatory response by releasing various cytokines and interacting with other cells. The main inflammatory cells involved in myocardial fibrosis include macrophages, mast cells, T lymphocytes and B lymphocytes. In myocardial fibrosis, inflammatory cells promote wound healing and tissue repair on the one hand (73), while on the other hand, they may lead to excessive tissue fibrosis. For example, mast cells tend to be antifibrotic in healthy hearts and promote fibrosis in diseased cardiac tissues (74, 75).

3.1.1 Macrophages

Macrophage (MC) is an immune cell with functions such as immune response, antigen presentation, and phagocytosis, and usually includes classically activated M1 macrophages, as well as alternatively activated M2 macrophages. MC play an important role in various immune processes, inflammatory responses, and fibrosis. Notably, macrophages, as the largest subset of immune cells in the heart (76), are important players in myocardial inflammation and fibrosis (77).

MC promote myocardial fibrosis through multiple pathways. MC directly enhance the survival and activation of myofibroblasts, resulting in increased ECM. In addition, infiltration of mononuclear macrophages is an obligatory process of inflammatory response, and inflammation is a key link in the formation of myocardial fibrosis (78). MC exacerbate the inflammatory response through the secretion of pro-inflammatory factors (e.g., TNF-α, IL-1β, etc.) and the expression of CD86-specific markers (79), while MC produce platelet-derived growth factor (PDGF) and other factors which can activate pro-fibrotic mediators in fibroblasts (80). In addition, after myocardial tissue injury, the associated malfunction of MC will lead to persistent myocardial injury, thus aggravating myocardial fibrosis (81). The malfunctions include abnormal repair, insufficient production of anti-inflammatory MC, and failure of communication between MC and various cells.

Both M1 and M2 macrophages exhibit bidirectional regulation in myocardial fibrosis. In the early stage of cardiac injury, M1 macrophages predominate and produce matrix metalloproteinases (MMPs) that promote ECM degradation, and secrete pro-inflammatory cytokines such as TNF-α and IL-6 that activate CFs (82). The activated CFs increase MMPs while secreting more pro-inflammatory cytokines, further enhancing the inflammatory response (83), which in turn leads to the continuous activation of M1 macrophages and the continuous production of MMPs, which leads to the continuous degradation of the ECM (78). The promotion or inhibition of M1 is mostly related to its mechanism of action, which is different for the M2 type.

In an animal model of angiotensin II-induced myocardial fibrosis, a matrix metalloproteinase-9 (MMP-9) knockout mouse model of myocardial infarction, and a mouse model of aging, M2 macrophages accumulate in large numbers and promote fibroblast activation and collagen synthesis and secretion (84). In animal models such as the IL-13 knockout mouse model of myocardial infarction and the diabetic cardiomyopathy model, M2 macrophages are reduced in injured cardiac tissues, but myocardial fibrosis is aggravated, which in turn suggests an inhibitory effect of M2 macrophages on myocardial fibrosis in these models (85, 86).

In summary, M1 and M2 macrophage make effects on the progression of myocardial fibrosis through multiple pathways.

3.1.2 Mast cells

Mast cells (MC) are innate immune cells that play an important role in innate immune response, acquired immune response, and CVD (87). They are distributed throughout the body, including the heart (88). Activated mast cells can undergo degranulation and release different proinflammatory factors and immunomodulatory mediators into the cellular microenvironment, such as histamine, proteases, and a variety of cytokines, growth factors, and chemokines. Mast cells are closely associated with the inflammatory response while promoting the development of myocardial fibrosis.

Mast cells in the heart promote the development of myocardial fibrosis mainly through degranulation. Mast cell degranulation releases a large number of fibrotic mediators, including histamine, trypsin, chymotrypsin, and various cytokines. Among these factors, TNF-α (89), TGF-β (90), and others are associated with the activation of cardiac fibroblasts. The increase of mast cells in the heart transduces TGF-β-mediated pro-fibrotic signaling, resulting in more pro-fibrotic responses in cardiac fibroblasts (91). In addition, histamine secreted by mast cells stimulates proliferation of fibroblasts and collagen synthesis (92, 93) Tryptase-like enzymes, by activating the protease-activated receptor 2 and inducing the corresponding signaling, result in cardiac fibroblasts with collagen synthesis increase (94). Chymotrypsin, on the other hand, has both synthetic and degradative effects on collagen fibers, promoting angiotensin II (95) production and activation of the TGF1/Smad protein pathway (96), thereby facilitating cardiac fibroblast proliferation and collagen synthesis. At the same time, chymotrypsin activates MMPs and degrades matrix proteins (97). However, it has been experimentally demonstrated that inhibition of chymotrypsin reduces myocardial fibrosis, but chymotrypsin still exerts a pro-fibrotic effect overall (98, 99). In addition to degranulation, mast cells play a unique effect on the development of myocardial fibrosis. In a model of fibrotic cardiomyopathy due to TNF-α overexpression, the development of cardiac fibrosis requires the interaction of mast cells and fibroblasts (91).

3.1.3 CD4+ helper T cells

T lymphocytes and their subpopulations are important components of immunity and are mainly divided into helper T cells (Th cells), regulatory T cells (Tregs cells), and suppressor T cells (Ts cells), and different subpopulations can secrete cytokines to participate in regulation of the inflammatory response (100). The main surface marker of suppressor T cells is CD4, and they are divided into cell subpopulations such as Th1, Th2, Th3, Th9, Th17, and T follicular helper cells, among which Th1, Th2, and Th17 are closely related to myocardial fibrosis.

Th1 cells secrete pro-inflammatory factors such as γ-interferon-γ (IFN-γ), TNF, and interleukin-12 (IL-12). IFN-γ, as a major inflammatory marker, inhibits Th2-mediated activation of fibroblasts and indirectly regulates fibrosis through activation of macrophages (101), and also can inhibit fibrosis through TGF-β-induced Smad3 phosphorylation (102). Meanwhile, Th1 cells can also stimulate the transformation of fibroblasts into collagen fiber-secreting myofibroblasts through direct cell-to-cell interactions (103). Th2 cells secrete factors such as IL-4, IL-5, and IL-13 to promote fibrosis (104). Among them, IL-4 induces the expression of GATA-binding protein 3 in a signal transducer and activator of transcription-6 (STAT-6)-dependent mechanism, which promotes the secretion of IL-4 and IL-5 and inhibits the production of IFN-γ (105). IL-17 secreted by Th17 induces matrix metalloproteinase-1 (MMP-1) production in human cardiac fibroblasts, degrades collagen and mediates tissue remodeling (106, 107).

In summary, CD4+ helper T cells affect myocardial fibrosis according to different cellular subpopulations, and their mechanism of action is mainly through their secreted cytokines.

3.1.4 Bursa dependent lymphocyte

Bursa dependent lymphocyte (B cell) are bone marrow-derived pluripotent stem cells with roles in antibody production, antigen presentation, and immunomodulatory cytokines, which are widely involved in the immune response process (108) and have an important impact on the cardiovascular system (109).

B cells are directly involved in cardiac remodeling through the upregulation of TGF-β1 and IL-6 and produce TNF-α, IL-1β, and IL-6 to maintain a deleterious inflammatory environment. In the study of dilated cardiomyopathy, B cells secreted TNF-α to exert proinflammatory effects and participate in and promote the process of myocardial fibrosis (110). In addition, activated B cells act as antigen presenters, activating CD4+ T cells and promoting their differentiation into the Th1 phenotype (111). Activation of B cells also activates a large number of immune-inflammatory pathways mediated by Toll-like receptors (TLRs), which promotes inflammatory responses and myocardial fibrosis (112). Moreover, activated B cells can recruit inflammatory monocytes Ly6C+ to the myocardium in a Chemokine (C-C motif) ligand 7 (CCL7)-dependent manner, leading to sustained inflammatory progression and myocardial fibrosis (113).

In summary, B lymphocytes can influence myocardial fibrosis by secreting or regulating relevant cytokines, and their activation plays an even more important role.

3.2 Inflammatory factors and myocardial fibrosis

3.2.1 TNF-α

Tumor necrosis factor-α (TNF-α), a cytokine with proinflammatory effects, is produced mainly by peripheral macrophages and monocytes, is involved in normal inflammatory and immune responses, and is involved in neutrophil chemotaxis in areas of injury (114). Myocardial fibroblasts secrete TNF-α in response to different types of injury; however, excessive TNF-α secretion leads to myocardial fibrosis.

TNF-α induces myocardial fibrosis through multiple pathways. TNF-α activates transcription factors such as AP1 (115) and WNT1 inducible signaling pathway protein 1 (WISP1) in cardiac fibroblasts, thereby promoting cardiac fibroblast proliferation and collagen secretion, contributing to the development of fibrosis (116). Meanwhile, TNF-α induces OS, which can cause myocardial tissues to overexpress TNF-α, further exacerbating myocardial interstitial fibrosis (117). In addition, TNF-α independently induces upregulation of the angiotensin II type 1 receptor (AT1R), which enhances angiotensin II-mediated pro-fibrotic effects (118). TNF-α also upregulates and activates MMPs, which are responsible for collagen degradation and subsequent matrix deposition, and thus promotes ECM accumulation (119).

Taken together, TNF-α can inhibit myocardial contractility and cause alterations such as fibrosis in cardiomyocytes through a variety of pathways, including activation of endothelial cells, recruitment of inflammatory cells, and increased production of inflammatory cytokines (120).

3.2.2 IL-6

Interleukin-6 (IL-6), IL-6 is a cytokine with multiple activities that is produced by macrophages, vascular smooth muscle cells, and fibroblasts, among others (121, 122). IL-6, as a proinflammatory cytokine, has been implicated in a variety of pathogenetic mechanisms, including inflammation and fibrosis, in CVD (123).

The fibrogenic effects of IL-6 involve direct actions on fibroblasts, as well as indirect effects related to macrophage recruitment, induction of matrix proteins, and up-regulation of growth factors with significant fibroblast-activating properties (like TGF-β) (124). IL-6 is a key component of the proinflammatory effects of calphostin-11 (CDH11) and hypoxia-induced mitogenic factor (HIMF) (125). The fibrogenic effect of IL-6 has been shown to be a major contributor to the inflammation of CVD. IL-6 is a signaling molecule downstream of CDH11 and HIMF, and activate MAPK and calcium-calmodulin dependent protein kinase II (CaMKII) signaling pathway. IL-6 and heat shock protein 90 (Hsp90) synergistically activate the signal transduction and transcriptional activator 3 (STAT-3) signaling pathway (125, 126), leading to excessive collagen synthesis and contributing to the development of myocardial fibrosis (127). In addition, IL-6 can regulate the development of high glucose-induced myocardial fibrosis by enhancing the expression of TGF-β1 and inhibiting the expression of miR-29, which promotes the regulation of myocardial fibroblast proliferation and collagen production (128).

In summary, the inflammatory factor IL-6 promotes the development of myocardial fibrosis by activating inflammatory signaling pathways such as MAPK and STAT3 and activating TGFβ-1 growth factor.

3.2.3 IL-1β

Interleukin-1β (IL-1β), as an isoform of IL-1, is an important pro-inflammatory cytokine, mainly produced by macrophages and monocytes, which plays a key role in the early stage of inflammation and has an important impact on CVD.

Unlike the production mechanisms of most inflammatory cytokines, the production of biologically active IL-1β is dependent on transcriptional, translational, maturation, and secretory mechanisms (129). IL-1β is a member of the nucleotide-binding oligomerization domain (NOD)-like receptor family of pyrin-containing proteins. IL-1β is a downstream inflammatory cytokine secreted by NOD-like receptor family, pyrin domain-containing protein3 (NLRP3) inflammasome, which can utilize the formation of cysteinyl aspartate specific proteinase1 (Caspase1) induced by NLRP3 inflammasome Caspase 1 to mediate the processing and activation of its own precursor to the active form. Activated IL-1β promotes the activation of transcription factors, which drives and enhances the expression of factors such as TGF-β1, IL-4, and IL-13 (130) and promotes myocardial fibrosis. In addition, chronic upregulation of IL-1β activates NLRP3 inflammatory vesicles, whose autocrine signaling to drive differentiation of fibroblasts into myofibroblasts (131). IL-1β also binds to phosphatidylinositol 3-kinase (PI 3) signaling, which through NF-κB upregulates the sustained production and activation of fibroblast growth factor 2 (FGF-2) (132, 133), which promotes endothelial-mesenchymal transition (End-MT), resulting in the gradual loss of endothelial cell morphology and function, and the acquisition of mesenchymal cells, and the loss of endothelial cell morphology and function, which acquires a mesenchymal cell or myofibroblast phenotype (134), regulating the development of myocardial fibrosis after acute myocardial infarction (AMI) (135).

Taken together, IL-1β functions as a factor downstream of NLRP3 inflammatory vesicles and participates in the process of myocardial fibrosis by promoting the production of factors such as TGF-β1 and activating FGF-2 to promote End-MT.

3.2.4 Gal-3

Gal-3, a member of the β-galactan lectin-binding lectin family, is a protein secreted mainly by macrophages, fibroblasts, mast cells, and neutrophils (136). Gal-3 is a biomarker of myocardial fibrosis, is widely expressed in the immune system, and is significantly involved in the process of myocardial fibrosis as a pro-inflammatory and pro-fibrotic molecule.

It has been shown that Gal-3 initially exerts a protective effect in the heart through its anti-apoptotic and anti-necrotic functions, but prolonged expression of this protein leads to the onset of fibrosis (137). Gal-3 enhances macrophage and mast cell infiltration, which promotes the release of inflammatory mediators, such as TGF and IL-1 or IL-2, creating a microenvironment enriched with pro-inflammatory cytokines, thereby promoting fibrosis (138). In addition, Gal-3 is a matricellular glycan-binding protein involved in myocardial fibrosis and remodeling, and activation of Gal-3 leads to its multimerization and formation of Gal-3 lattices on the cell surface, which enhance fibrotic signaling by trapping the TGF-β receptor on the cell surface, and these signaling factors, along with mechanical stresses, promote the transition of quiescent fibroblasts to active, collagen-producing myofibroblasts, thereby inducing the onset of myocardial fibrosis (73, 139, 140). Most importantly, the major binding sites for Gal-3 are located in the extracellular matrix of cardiac fibroblasts and macrophages. Upon myocardial damage, Gal-3 is released at the site of injury and activates resting fibroblasts into matrix-producing fibroblasts by increasing the synthesis of cytoskeletal proteins, such as type I collagen, and inhibiting the activity of MMPs.

In summary, Gal-3 can promote the process of myocardial fibrosis by promoting the development of inflammation, forming Gal-3 lattice to enhance fibrotic signaling, increasing the synthesis of cytoskeletal proteins, and inhibiting the activity of MMPs, and plays an important role in myocardial fibrosis.

3.2.5 IL-16

Interleukin-16 (IL-16) is mainly secreted by T-lymphocytes, epithelial cells, fibroblasts, and monocytes, and has been shown to be a key mediator of several inflammatory, allergic or infectious diseases, as well as playing an important role in promoting myocardial fibrosis (141). Modern studies have shown that IL-16 plays a central role in promoting myocardial fibrosis by prompting the release of TGF-β1 from macrophages infiltrated with cardiomyocytes. In addition, IL-16 enhances the secretion of inflammatory cytokines such as IFN-γ, IL-10, IL-16, TNF-α, and IL-15 by monocytes and mature macrophages, which promotes the development of myocardial inflammation and thus plays an indirect role in promoting the development of myocardial fibrosis (142).

3.2.6 IL-17

Interleukin-17 (IL-17) is a more specific pro-inflammatory cytokine that belongs to a new family of cytokines with no homology to other known interleukins, which are expressed in immune or non-immune cells (143), with IL-17A playing a key role in both myocardial inflammation and myocardial fibrosis. IL-17A specifically acts during the late stage of myocardial remodeling to promote sustained macrophage infiltration and stimulate their production of proinflammatory cytokines, enhancing fibroblast proliferation and pro-fibrotic gene expression (144). In addition, IL-17A increases the expression of MMPs, TIMPs, and collagen, leading to fibroblast migration and myocardial remodeling, resulting in excessive accumulation of interstitial collagen (145).

3.2.7 IL-27

Interleukin-27 (IL-27) is mainly produced by activated antigen-presenting cells such as monocytes, macrophages and dendritic cells (146) and is a member of the Interleukin-12 (IL-12) family, which consists of the α-subunit, IL-27p28, and the β-subunit, Epstein Barr virus induced protein 3 (EBI3) (147). Numerous studies have confirmed that IL-27 not only promotes myocardial fibrosis by acting independently, but also indirectly promotes the process of myocardial fibrosis by activating related signaling pathways. IL-27 regulates the function of fibroblasts and promotes the differentiation of fibroblasts into myofibroblasts, which directly promotes myocardial fibrosis. Meanwhile, IL-27 promotes the activation of Janus kinases (JAKs)/STAT signaling pathway in myocardial fibroblasts, which is involved in the process of myocardial fibrosis (148).

3.2.8 IL-4

Interleukin-4 (IL-4) is an anti-inflammatory cytokine produced by CD4T lymphocytes and mast cells (149, 150). Some experimental studies in mice have shown that IL-4 is an important factor in myocardial cardiac fibrosis in hypertensive hearts (151). In disease states, IL-4 activates mast cells (152), which are pro-fibrotic (153). At the same time, IL-4 produced by mast cells may act in an autocrine manner, leading to further mast cell proliferation and IL-4 production, exacerbating the fibrotic process (154). In addition, IL-4 helps to increase the number of macrophages in fibrotic hearts (155). Moreover, high concentrations of IL-4 can induce macrophage polarization toward an M2 phenotype that inhibits inflammation and promotes scarring (156), a process that has been shown to promote the process of myocardial fibrosis. In addition to this, IL-4 can promote myocardial fibrosis by upregulating collagen genes and stimulating collagen production in mouse CFs, mediated through the signal transducers and activators of transcription 6 (STAT6) signaling pathway (154).

3.2.9 IL-10

Interleukin-10 (IL-10), a multi effector cytokine produced mainly by T helper cells and monocytes/macrophages, has anti-inflammatory effects and promotes the process of tissue healing in injuries caused by infections or inflammation (157). IL-10 is generally believed to inhibit myocardial fibrosis through activation of the STAT3 signaling pathway (158). However, it has been shown that IL-10 produced by myocardial macrophages indirectly activates fibroblasts and stimulates collagen deposition when diastolic dysfunction occurs. Although IL-10 may be beneficial for inflammatory regression and wound healing, it may also have pro-fibrotic deleterious effects in chronic disease settings (159). The in vivo effects of IL-10 in the myocardial fibrotic response may depend on the balance between their anti-inflammatory and pro-myocardial fibrotic effects.

3.2.10 IL-33

Interleukin-33 (IL-33), a member of the IL-1 family, is constitutively expressed in the nuclei of endothelial and epithelial cells of normal human tissues (160) and is a biomechanically inducible protein synthesized primarily by CFs (161). The receptor for IL-33 is the growth stimulation expressed gene 2 protein (ST2). ST2 has 2 major isoforms: transmembrane and soluble forms (162). The IL-33/transmembrane ST2l signaling pathway (163), which exerts a protective effect in heart failure, is pro-fibrotic when soluble ST2 binds IL-33 (164, 165). IL-33 is anti-inflammatory and antifibrotic depending on the balance between IL-33 and ST2. In addition to this, IL-33 induces an immune response in Th2 cells, releasing IL-13 and IL-5 (162).

3.3 Inflammatory pathways and myocardial fibrosis

Inflammatory response is the main cause of myocardial fibrosis, which is mainly regulated by inflammatory pathways. Inflammatory factors can mediate or be components of inflammatory pathways.

3.3.1 NF-κB

NF-κB is recognized as a classic inflammatory signaling pathway and is widely present in a variety of cells, with a family of five subunits including Rel, RelB, p65 (RelA, NF-κB3), p50 (NF-κB1), and p52 (NF-κB2). NF-κB is involved in the cellular response to inflammatory and stimulatory factors and plays an important role in the pathogenesis of inflammation and fibrosis in the myocardium (166).

The NF-κB signaling pathway promotes the process of myocardial fibrosis through two main pathways. First, NF-κB activation induces the accumulation of inflammatory factors (e.g., TNF-α, IL-1β, IL-6, IL-18, etc.) in myocardial tissues, resulting in increased inflammatory response and consequently myocardial injury, which promotes the proliferation of myocardial fibroblasts and collagen deposition, and ultimately induces the onset of myocardial fibrosis. Second, the homodimer or heterodimer formed by p65 binds to κB protein inhibitors in the cytoplasm, causing IκB degradation and release of NF-κB dimers, which in turn translocates NF-κB into the nucleus, whereas NF-κB, as a central transcriptional effector of inflammatory signaling, will turn on the transcription of target genes (167). In addition, the activation and nuclear translocation of NF-κB can induce the transcription of chemokines [monocyte chemotactic protein-1 (MCP-1)], cytokines (TNF-α, IL-6), and MMPs, and these transcriptionally increased factors greatly contribute to the process of myocardial inflammation and fibrosis through multiple pathways (168).

In summary, NF-κB activation induces the accumulation of other inflammatory factors and nuclear translocation, thereby initiating the transcription of inflammation-related target genes, which play a crucial role in promoting the process of myocardial fibrosis as an important pathway mediating myocardial inflammation.

3.3.2 MAPK

The mitogen-activated protein kinase (MAPK) pathway is a class of phosphorylation-mediated tertiary kinase cascade signaling involved in cell proliferation, differentiation, apoptosis, and fibrosis (169). P38 mitogen-activated protein kinase (p38 MAPK), as the major isoform of the MAPK family, also known as extracellular signal-regulated kinase, regulates inflammatory factors and OS damage in vivo (170, 171), and is involved in the pathological process of cellular fibrosis.

The P38 MAPK signaling pathway is activated by the action of angiotensin II (Ang II) on its type 1 receptor, which activates its downstream transcription factors, prompting the massive synthesis and release of TGF-β in cardiomyocytes, leading to the massive proliferation of myocardial fibroblasts, increased expression of collagen, and imbalance of the ratio of type I./III. collagen (172), which ultimately causes myocardial fibrosis. It has been demonstrated that p38 MAPK transduces cytokines and mechanical signals into myofibroblast differentiation through serum response factor (SRF) and calcineurin (CN) (173). In addition, increased levels of p38 in CFs are associated with elevated expression of inflammatory cell-related genes and proteins, and the inflammatory factors produced can exacerbate myocardial fibrosis by activating the p38MAPK pathway in CFs (174).

In summary, the P38MAPK signaling pathway promotes myofibrillar activation to drive the development of myocardial fibrosis by increasing the production of downstream factors such as TGF-β and inflammatory factors.

3.3.3 TGF-β/Smad

Transforming Growth Factor-β (TGF-β) is a multifunctional mediator with three isoforms (TGF-β1, TGF-β2, and TGF-β3) that has been closely associated with a variety of fibrotic processes (175), with TGF-β1 being a key mediator in the development of fibrosis and inflammation. The Smad protein family of Smad2 and Smad3 are two major downstream regulators that promote TGF-β1-mediated tissue fibrosis (176). It has been shown that TGF-β/Smad is a pleiotropic signaling pathway that plays a key role in inflammation and fibrosis, with TGF-β1/Smad considered one of the major pathways inducing the onset of cardiac fibrosis (177).

The promotion of myocardial fibrosis by TGF-β1/Smad is multifaceted. Several studies have shown that TGF-β1 can upregulate the expression of chemokines and proinflammatory factors in both tethered and inflammatory cells, which promotes the development of inflammation, which in turn leads to myocardial fibrosis (178). It has been found that TGF-β mediates inflammation-related myocardial fibrosis can be induced by inducing quiescent fibroblasts to activate and differentiate into extracellular matrix protein-secreting myofibroblasts (179). Among the signaling pathways induced by TGF β, both Smad-dependent and Smad-independent pathways promote cardiac fibrosis (180). Among them, the Smad-independent pathway involves members of the MAPK family. TGF-β stimulates three known MAPK pathways, namely, extracellular signal-regulated kinase, Jun N-terminal kinase, and the p38 pathway (181–183). Transcription factors, which are the primary targets for activation of MAPK, are then stimulated, leading to the initiation of many downstream signaling transductions. These downstream signaling pathways, such as the ERK1/2 signaling pathway, play a pivotal role in inflammation and myocardial fibrosis. In addition, TGF-βs also function in the downregulation of the miR-29 family, and inhibition of the miR-29 family leads to an increase in several key ECM proteins and collagens, which subsequently trigger myocardial fibrosis (172).

In conclusion, the TGF-β/Smad pathway influences the course of myocardial fibrosis either through its pro-inflammatory and contributing pathways to fibroblast differentiation, or through activation of other signaling pathways, modulation of miRNAs, etc.

3.3.4 JAK2/STAT3

The Janus protein tyrosine kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway is an important intracellular signal transduction pathway. This pathway is activated in response to protein ligands, including cytokines, growth factors, interferons, and peptide hormones, which in turn regulate a variety of cellular processes, including cell growth, proliferation, differentiation, and apoptosis (184). And it has been closely associated with myocardial fibrosis.

The JAK2/STAT3 pathway is activated by the binding of inflammatory cytokines, such as IL-6, to its specific receptor (185) and stimulates the expression of cytokines, such as IL-6, thereby increasing the inflammatory response and promoting myocardial fibrosis. The activation of the JAK2/STAT3 pathway by resistin up-regulates genes related to fibrosis (186). In addition to this, STAT3 is a key molecular checkpoint for fibroblast activation, which integrates and translates JAK2 kinase activation into a pro-fibrotic response, which in turn induces myofibroblast differentiation and upregulates collagen release (187). In addition, STAT3 is an atypical downstream mediator that transmits the apoptotic effects of TGF-β. Knockdown of STAT3 in fibroblasts prevents TGF-β-induced differentiation of resting fibroblasts to myofibroblasts and significantly reduces the stimulatory effects of TGF-β on collagen release (187). Activation of STAT3 also regulates Angiotensin II (Ang II)-induced cardiac remodeling and is a negative regulator of ventricular hypertrophy and fibrosis (188). Inhibition of STAT3 prevents Ang II-induced fibrosis and cardiac function defects.

Taken together, the JAK2/STAT3 pathway promotes myocardial fibrosis by promoting inflammatory responses, inducing differentiation of myofibroblasts, and transmitting the apoptotic effects of TGF-β.

3.4 NLRP3 inflammatory vesicles and myocardial fibrosis

NOD-like receptor protein 3 (NLRP3) is one of the representative inflammatory vesicles of the NOD receptor family and an inflammatory complex protein that has attracted a lot of attention in recent years (189). The NLRP3 inflammasome consists of the receptor NLRP3, the junction protein ASC, and the effector protein pro-caspase-1 (190) and is widely expressed in various cytoplasms. In cardiac fibroblasts, inappropriate activation of NLRP3 inflammatory vesicles can lead to a variety of myocardial dysfunctions including myocardial fibrosis (191).

Under physiological conditions, NLRP3 inflammasome-mediated proinflammatory responses maintain homeostasis and form a protective mechanism for the body (192). Upon myocardial damage, NLRP3 inflammatory vesicles are activated, and after converting pro-caspase-1 to caspase-1, they cleave inflammatory factor precursors, such as pro- IL-1β and pro-IL-18, into mature IL-1β and IL-18 and release them extracellularly. Thereby mediating the development of myocardial inflammation and thus contributing to the onset of myocardial fibrosis (193). Second, NLRP3 inflammatory vesicles activate the TGF-β/Smad and MAPK signaling pathways, which in turn lead to myocardial fibrosis through various pathways, including the promotion of inflammatory factor recruitment (194). In addition, NLRP3 inflammasome activates sterile inflammatory response by recognizing damage-associated molecular pattern (DAMP) in damaged cells (195). And sterile inflammation is closely associated with the levels of pro-inflammatory factors (e.g., TNF-α, IL-6, and IL-1β) that can induce myocardial fibrosis.

In summary, NLRP3 inflammatory vesicles affect the development of myocardial fibrosis mainly through three pathways: cleavage and release of mature inflammatory factors, activation of inflammation-related pathways, and activation of sterile inflammatory responses (Figure 4).

Figure 4

Figure 4. Inflammatory response and myocardial fibrosis. The mechanisms by which the inflammatory response promotes myocardial fibrosis involve multiple aspects of inflammatory cells, inflammatory factors, inflammatory pathways and inflammatory vesicles. Inflammatory cells can secrete inflammatory factors, and inflammatory factors can further activate the inflammatory pathway to act on myocardial fibroblasts, promoting their activation and secretion of extracellular matrix, which in turn promotes the development of myocardial fibrosis. Created in BioRender. Li R (2025) https://BioRender.com/6beszmg.

4 Natural medicine and active ingredients modulate myocardial fibrosis by alleviating the inflammatory response

4.1 Traditional Chinese medicine active ingredients

4.1.1 Flavonoids

4.1.1.1 Curcumin

Curcumin is a natural product extracted from turmeric (Curcuma Longa Rhizoma), a plant of the ginger family, and has a variety of antioxidant, anti-inflammatory, anti-tumor, and anti-microbial effects. It reduces inflammation in myocardial fibrosis by inhibiting some signaling pathways, such as MAPKs (196), phosphatidyl-inositol 3-kinase (PI3K) (197), TGF-β (198), and NF-κB (199), and reducing MMP-9 and MMP-2 (200).

Curcumin inhibited Adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK)/p38 MAPK pathway in rat myocardium by inhibiting TGF-β1 and typical Smad signaling, blocking the synthesis of collagen associated with diabetes (201). Curcumin also reduced the number of advanced glycation end products (AGEs) and the receptor of advanced glycation end products (RAGE) in diabetic rats, thereby inhibiting the activation of MAPKs, PI3K, and NF-κB signaling pathway activation (197). Studies have shown that the combination of curcumin and metformin inhibits JAK/STAT by activating the nuclear factor E2-related factor 2/heme oxygenase-1 (Nrf2/HO-1) pathway and decreasing TGF-β1, thereby attenuating OS and inflammatory responses, which in turn inhibits cardiac fibrosis (202). Also, curcumin inhibits cardiac fibrosis by activating Nrf2, Glutamate-Cysteine Ligase Catalytic Subunit (GCLC), HO-1, and NAD(P)H: quinone oxidoreductase 1 (NQO1) antioxidant effects in vitro and in vivo, attenuating palmitate-induced ROS increase, inflammation, apoptosis and hypertrophy (201). In addition, curcumin inhibits p38 and c-JunN-terminal kinase (JNK) pathways by increasing the expression of Dickkopf-related protein 3 (DKK-3), which in turn decreases MMP-2 and MMP-9, leading to ECM degradation and vascular degeneration, and attenuates chronic heart failure (CHF) rabbit myocardial fibrosis (202).

4.1.1.2 Licorice glycosides

Glycyrrhizin is a dihydroflavonoid extracted from Gancao, which has a variety of pharmacological effects, including antidepressant, anti-inflammatory, antitumor, and cardiovascular protection.

It was found (203), that glycyrrhizin reduced myocardial fiber alignment disorders, inflammatory cell infiltration, and collagen deposition, thereby improving myocardial fibrosis. Liguiritigenin significantly reduced collagen I, collagen III, TGF-β1, MMP-9, α-smooth muscle actin (α-SMA), CCL5, p-NF-κB, TNF-α, and IL-6 expression by inhibiting the expression of CC motif chemokine ligand 5 (CCL5) and NF-κB pathway. Another study (204) also reported that Liquiritin attenuated myocardial fibrosis by reducing the expression of type I collagen, type II collagen, MMP-9, and α-SMA. In addition, another study showed that liquiritin reduced the release of inflammatory cytokines and phosphorylation of NF-κB by inhibiting the IKKα/IκBα signaling pathway.

4.1.1.3 Mangiferin

Mangiferin is a diphenylpyranone flavonoid, which not only exists in mango, but also in a variety of natural medicine, such as Han Lian Cao, Long Dan Cao, Gou Teng, Ban Lan Gen, Ci Wu Jia Ye, and Zhi Mu. It has a variety of beneficial effects such as anti-tumor, immunomodulation, antioxidant, and anti-inflammatory.

Mangiferin inhibits cardiac collagen deposition while decreasing the levels of cardiac inflammatory cytokines, including IL-1β, IL-6, and TNF-α, as well as the expression of TGF-β1, p-p38, p-MAPK-activated protein kinase 2 (MK2), collagen I (Col-I), collagen III (Col-III) and α-SMA. This suggests that mangiferin inhibits the D-galactose-induced cardiac pro-fibrotic TGF-β1/p38/MK2 signaling pathway, thereby ameliorating cardiac fibrosis (205). Mangiferin inhibits macrophage-associated cytokines, including CD68, monocyte chemotactic protein-1, and TGF-β1, thereby attenuating fructose-induced cardiac interstitial fibrosis (206). Mangiferin also inhibits the p38 MAPK cascade, reducing apoptosis and fibrosis during myocardial remodeling (207). Mangiferin reduces the levels of pro-inflammatory cytokines, pro-apoptotic proteins, and TGF-β, as well as the phosphorylation of p38, thereby alleviating myocardial fibrosis in rats with myocardial ischemia-reperfusion injury (208). In addition, mangiferin reduced the number of inflammatory cells and the area of fibrosis in doxorubicin-induced cardiotoxicity rats (209).

4.1.1.4 Hypericum glycosides

Hypericin, a flavonol glycoside extracted from many traditional natural medicine, has a variety of pharmacological effects including antioxidant, hypoglycemic, anticancer, anti-inflammatory, and cardioprotective.

Hypericin attenuates inflammatory cell infiltration and inhibits the NLRP1 inflammatory pathway by upregulating autophagy (210), thereby inhibiting TGF-β1-induced myofibroblast differentiation and EMC overproduction in neonatal cardiac myofibroblasts by targeting the TGF-β1/Smad signaling pathway (211). Hypericin limits cardiac interstitial fibrosis and inflammatory cell infiltration. The mRNA expression of fibrosis markers, including collagen I, collagen III, and CTGF, the phosphorylation of TGF-β1, Smad2, and Smad3, as well as the expression of IL-1a, IL-6, TNF-α, and MCP-1, were attenuated in the presence of hypericin (212).

4.1.1.5 Biochanin A

Biochanin A is an isoflavonoid found in Tu Jin Pin, Ge Gen, San Leng Cao, and Deng's Ci Wu Jia. Many studies have shown that Biochanin A has anti-inflammatory, antioxidant, antimicrobial, and anticancer properties.

Bioflavonoid A significantly reduced the protein levels of collagen III, α-SMA, NLRP3, and p-SMAD, and inhibited the migration and proliferation of fibroblasts (213). Bioflavin A was shown to reduce serum collagen-I, tissue collagen-III, and hydroxyproline levels, resulting in an improvement in isoprenaline-induced myocardial fibrosis. The combination of biotin A and isoprenaline significantly reduced IL-6 expression, whereas brain natriuretic peptide (BNP) and α-SMA were slightly inhibited (214).

4.1.2 Quinones

Tanshinone is a fat-soluble diterpene quinone extracted from the dried roots of Dan Shen Bunge. It possesses chemistry activities including antioxidant (215), anti-inflammatory (216), antifibrotic (217), antiviral, antitumor (218), antiplatelet aggregation and neuroprotective (219) ect.

Tanshinone inhibits myocardial fibrosis by inhibiting the phosphorylation of Smad2/3 in rat CFs (220), which reduces the nuclear translocation of Smads and the expression of fibronectin genes (221, 222), as well as decreases the protein levels of fibroblast markers, such as α-SMA, collagen I and III, periosteum proliferating protein and TGF-β, and increases the number of MMP-1 in AngII-treated CFs (223, 224), thereby interfering with the Smad-dependent TGF-β pathway. It was found that myocardial infarction mice with tanshinone administration had fewer necrotic cardiomyocytes at the site of myocardial infarction, regular cellular arrangement, and reduced inflammatory cell infiltration (225). It was also found subsequently that the combination of tanshinone and Puerarin in a 1:1 ratio significantly attenuated acute ischemic cardiomyocyte injury and structure of interstitial edema myocardium, and decreased collagen synthesis and fibroblast release, thereby inhibiting myocardial fibrosis and cardiac remodeling.

4.2 Single-ingredient traditional Chinese medicine

4.2.1 Dan shen

Dan Shen injection prevents heart failure by attenuating post-infarction remodeling. Yan et al. explored the potential role of the small molecule miR-618 in the anti-myocardial fibrosis of Tanshinone IA, and found that elevated levels of miR-618 could promote the inhibition of cardiac tissue hypertrophy and collagen deposition by Tanshinone IA, and enhance the anti-fibrotic activity of Tanshinone IA (226). The results of the study showed that Tanshinone IA could reduce the incidence of myocardial infarction and enhance myocardial function. Using transcriptome sequencing technology (RNA sequencing, RNA-seg), the study identified 52 gene targets related to myocardial ischemic infarction, of which 21 were inflammation-related genes, and 16 were genes related to the MAPK cascade reaction, and it was further found that salvianolic acid A could reduce the expression of inflammatory factors such as IL-18, IL-6 and TNF-α, increase the quantity of thioredoxin (Trx) and inhibit the activation of JNK pathway, thus inhibiting apoptosis and inflammatory response, and alleviating the effects of myocardial infarction (227). The active ingredients of Dan Shen may play an anti-atherosclerosis (AS) role by lowering blood lipids and inhibiting inflammatory response through the TLR4/NF-κB signaling pathway (228). Danhong injection, danshen polyphenate injection, and danshen injection, which are based on the water-soluble components of Dan Shen, are also widely used in the emergency treatment of clinical CVD.

4.2.2 Tie Pi Shi Hu

Tie Pi Shi Hu attenuates diabetic cardiomyopathy by inhibiting OS, inflammation and fibrosis induced by streptozotocin in mice. By designing a mouse model, it was found that Dendrobium polysaccharides were able to ameliorate functional abnormalities caused by myocardial fibrosis by restoring the activity of aquaporin-5 through the inhibition of lymphocyte infiltration, as well as release of inflammatory factors and apoptosis caused by lymphocyte infiltration (229). In addition, the regulatory effects of Dendrobium polysaccharides on the immune system were investigated in isolated mouse spleens and the RAW264.7 macrophage cell line, and it was found that Dendrobium polysaccharides promoted proliferation of splenocytes, enhanced natural killer cell-mediated cytotoxicity, increased macrophages phagocytosis and production of nitric oxide (NO), and stimulated the secretion of cytokines such as IL-1, IL-2 and TNF-α produced by splenocytes and macrophages (230). The aqueous extract of Tie Pi Shi Hu had a cytoprotective effect in an in vitro high glucose-induced OS cell model and a lipopolysaccharide-induced cellular inflammation model, which also has dose-dependent manner, and the mechanism of this protective effect may be related to the intracellular OS and inflammatory response through inhibition (231).

4.2.3 Huang jing

The main active ingredient of Huang Jing is Polygonatum sibiricum polysaccharide (PSP), which has antiviral, antioxidant, and anti-inflammatory properties, can improve OS levels and inhibit myocardial tissue OS and inflammatory responses, and ameliorate isoproterenol-induced cardiac remodeling in mice (232). It was found (233) that PSP could protect ARPE-19 cells from high glucose-induced OS, inflammation, and apoptosis by inducing the activation of Nrf2/HO-1 signaling pathway. In addition, PSP mitigated the effects of inflammatory cytokines by promoting Nrf2 expression (234). PSP also attenuated diabetic cardiomyopathy in diabetic mice by increasing cyclic guanosine monophosphate-protein kinase G signaling (235). in vitro antioxidant activity tests showed that PSP1 had scavenging effects on DPPH, hydroxyl radicals, superoxide anion radicals, and a specific chelating capacity for ferrous iron. This suggests that PSP is useful as a potential antioxidant for the treatment of myocardial fibrosis (236).

4.2.4 Huang Qi

Huang Qi and the active ingredients in its formulation, especially astragaloside IV, astragaloside polysaccharides, astragaloside total saponins, astragaloside triterpene saponins, and cycloastragalol, have potential efficacy against MF. It was demonstrated that compared with ischemia-reperfusion-injured rats, Astragaloside IV (ASIV) pretreatment group significantly inhibited malondialdehyde (MDA) levels and induced the Super Oxide Dismutase (SOD) and succinate dehydrogenase (SDH) in myocardial tissues, as well as inhibiting total protein expression of Nrf2 and H0-1 in cardiomyocytes, and decreasing the ratios of p-AKt to AK and p-ERK1/2 to ERK112, suggesting that ASIV exerts its anti-oxidative stress effects through inhibition of the Nrf2/HO-1 pathway (237). It was demonstrated (238) that ASIV inhibited the activation of p38 and JNK signaling pathways while promoting the activation of ERK signaling pathway and prevented high glucose/high fat and hypoxia-induced apoptosis in rat embryonic cardiomyocytes. ASIV decreased adriamycin (ADR)adri-induced Bcl-2-associated X protein/B-cell lymphoma-2 (BaX/BCL-2) ratio and the increase in the number of TUNEL-positive cells, effectively inhibited cardiomyocyte apoptosis. Some experimental results showed that compared with the control group, the left ventricular systolic pressure (LVSP), fractional shortening (FS), and ejection fraction (EF) in the 5 mglkgAs-IV and 10 mgkgAS-V groups were significantly increased, while LVEDP, lactate dehydrogenase (LDH), creatine kinase (CK), heart weight/body weight (HW/BW) ratio and myocardial infarction area were significantly lower (239). This suggests that As-V attenuates myocardial I/R injury in rats through inhibit the PI3K/AKT/glycogen synthase kinase-3 beta (GSK-3B) signaling pathway. There are also findings suggesting that transient receptor potential melastatin 7 (TRPM7) mediated Ca2 + signaling is required for TGF-β induced myocardial fibrosis and could serve as a common pathway in the fibrotic cascade response (240).

4.3 Traditional Chinese medicine compound formulas

4.3.1 Compound danshen dripping pill

Compound danshen dripping pill (CDDP) is a kind of proprietary Chinese medicine made by modern medical technology, which is composed of San Qi, Dan Shen and Bing Pian. Tanshinone IA and danshensu contained in Dan Shen can dilate blood vessels and reduce myocardial ischemia/reperfusion injury. Ginsenosides and Panax notoginseng saponins in San Qi inhibit OS and myocardial fibrosis, and Bing Pian has anti-inflammatory and analgesic effects and reduces myocardial oxygen consumption (241, 242). CDDP protects the myocardium through anti-inflammation, anti-oxidative stress, anti-fibrosis, and pro-angiogenesis, and has been widely used in clinical practice for the treatment of coronary artery disease, angina pectoris, and other CVD (243, 244).

Anti-inflammation is the main mechanism by which CDDP exerts cardioprotective effects, and CDDP can inhibits a variety of inflammatory factors and related pathways. Oral CDDP significantly reduced the levels of inflammatory factors such as TNF-α, NF-κB, and IL-6, and ameliorated myocardial injury (245). JNK signaling is a key component of the MAPK pathway, which plays an important role in the inflammatory progression of CVD (246). CDDP inhibits the pro-inflammatory activity of JNK by forming hydrogen-bonded binding to the kinase structural domains of JNK, thereby decreases cardiomyocyte apoptosis (245). In heart-injured mice, both Wnt and lysine-specific demethylase 4A (KDM4A) pathways were significantly activated, inducing inflammation and OS. CDDP exerted anti-inflammatory effects by inhibiting KDM4A activity (247). In addition, CDDP down-regulates forkhead box-O1(FoxO1) and reduces leukocyte adhesion, thereby inhibiting microcirculatory inflammation and improving microvascular function (248).

In summary, CDDP regulates inflammatory response mainly by affecting factors such as TNF-α, NF-κB, IL-6, JNK, KDM4A, and FOXO1, thus inhibiting myocardial fibrosis and improving cardiac function.

4.3.2 Qiliqiangxin

Qiliqiangxin(QL) is extracted from 11 herbs: Huang Qi, Ren Shen, Fu Zi, Dan Shen, Ting Li Zi, Ze Xie, Gui Zhi, Yu Zhu, Hong Hua, Xiang Jia Pi, and Chen Pi. A multicentre randomised double-blind study confirmed the efficacy of QL in chronic heart failure, and the cardioprotective mechanism of action of QL involves anti-inflammatory, improved energy metabolism and pro-angiogenesis (249–251).

QL regulates microRNAs and a variety of inflammatory factors and plays an important role in attenuating myocardial fibrosis. QL inhibits IL-6 mediated transformation of myocardial fibroblasts, thereby suppressing myocardial fibrosis and cardiac remodeling (252). QL down-regulates the TGF-β1/Smad3 signaling pathway through inhibition of the NLRP3 inflammatory vesicle, thereby suppressing myocardial inflammation and myocardial fibrosis (253). QL also down-regulates the Toll-like receptor 4 (TLR4)/NF-κB signaling pathway and up-regulates the TGF-β3/Smad7 signaling pathway, thereby attenuating cardiac remodeling after myocardial infarction (254). In addition, microRNA regulation is also involved in the anti-fibrotic mechanism of QL. QL inhibits the TGF-β1/Smad3 signaling pathway through up-regulation of miR-133a and miR-345-3p, thereby attenuating myocardial fibrosis and improving cardiac function (255, 256).

In summary, the mechanism of QL treat of myocardial fibrosis is mainly related to the down-regulation of TGF-β1/Smad3, in which inflammatory mediators like NLRP3, miR-133a and miR-345-3p play an important role.

4.3.3 Buyang huanwu decoction

Buyang Huanwu decoction (BYHWD) is a famous formula with a long history, which consists of Huang Qi, Dang Gui, Chi Shao, Chuan Xiong, Tao Ren, Hong Hua, and Di Long. BYHWD has been widely used in the prevention and treatment of CVD because of its anti-inflammatory, anti-OS (257), and reparative neurovascular (258) properties.

BYHWD regulates multiple inflammatory factors and inhibits collagen synthesis, playing an important role in inhibiting myocardial fibrosis. BYHWD reduces the release of pro-inflammatory factors through down-regulation of the JAK/STAT pathway, which attenuates left atrial myocardial fibrosis (259, 260). BYHWD down-regulates the expression of MMP9 in rat cardiac fibroblasts, which inhibits inflammatory responses and reduces the proliferation of cardiac fibroblasts (261). BYHWD down-regulated IL-18, NLRP3 inflammatory vesicles, and TLR4/NF-κB signaling pathway by inhibiting the TLR4 signaling pathway, and suppressed the expression level of collagen I/III, thereby attenuating cardiac inflammation and myocardial fibrosis after myocardial infarction (262).

In summary, BYHWD exerts anti-inflammatory effects by down-regulating the expression of inflammatory factors such as IL-6, IL-1β, IL-18, and NLRP3, and inhibiting the JAK/STAT and TLR4/NF-κB signaling pathways, thereby slowing down the process of myocardial fibrosis.

4.3.4 Qi shen Yi Qi pill

Qi Shen Yi Qi pill (QSYQ) is composed of four herbs, Huang Qi, Dan Shen, San Qi, and Jiang Xiang You, which have pharmacological effects such as anti-inflammatory, anti-OS, and inhibition of ferroptosis, and are widely used in China for the treatment of CVD such as coronary heart disease and heart failure (263–265).

QSYQ has significant advantages in improving myocardial fibrosis by modulating autophagy and inflammatory pathways. Hyperactivation of autophagy promotes the transformation of fibroblasts to a myofibroblast phenotype, which predisposes to induce myocardial collagen deposition and myocardial fibrosis. Beclin1(BECN1), MAP1LC3(LC3B) (including both LC3-I and LC3-II isoforms) and p62 are the most commonly used autophagy associated markers, and the PI3K/Akt-mammalian target of rapamycin (mTOR) pathway is a key upstream signaling pathway regulating autophagy (266). QSYQ down-regulates Beclin-1 and LC3-II/LC3-I expression, up-regulates p62 expression, and activates the PI3K/AKT-mTOR pathway to dose-dependently inhibit cardiac over-autophagy, thereby slowing down the process of myocardial fibrosis (267). QSYQ inhibited the TGFβ1/Smads signaling pathway and NLRP3 inflammatory vesicle expression, and significantly suppressed monocyte infiltration and macrophage polarization toward M2, thereby inhibiting MMP-2 and MMP-9 expression and ameliorating I/R induced myocardial fibrosis (268, 269). QSYQ down-regulated the TNF-α-NF-κB and IL-6-STAT3 signaling pathways that QSYQ inhibited type I and type II collagen synthesis, thereby improving myocardial remodeling and inhibiting myocardial fibrosis (270). QSYQ inhibited RAAS activation pathway and thereby down-regulated protein expression in the arachidonic acid (AA) metabolic pathway, thereby inhibiting myocardial fibrosis (271).

In summary, QSYQ inhibits NLRP3 inflammatory vesicles and inflammatory signaling pathways such as TGFβ1/Smads, STAT3, and NF-κB, and has multi-target anti-myocardial fibrosis properties.

4.3.5 Gualou xiebai decoction

Gualou Xiebai decoction (GXD) is a long-established Chinese medicinal preparation composed of Gua Lou and Xie Bai, which contains a variety of compounds that own mechanisms to regulate energy homeostasis and inhibit apoptosis, exerting potential cardioprotective effects (272, 273).

GXD mainly exerts anti-inflammatory effects by inhibiting NF-κB and other pathways and related factors, thereby inhibiting the process of myocardial fibrosis. GXD down-regulates the expression of NF-κB target cytokines such as TNF-α, monocyte chemotactic protein-1 (MCP-1), and inhibits the TGFβ1/Smads signaling pathway, thereby inhibiting myocardial type I and type II collagen synthesis and attenuating the cardiac injury cuase by myocardial fibrosis (274, 275) (Figure 5, Table 1).

Figure 5

Figure 5. Natural medicine and active ingredients regulate myocardial fibrosis. The active ingredients of Chinese medicines have multi-target and multi-pathway action characteristics, curcumin reduces MMP-2 and MMP-9 by inhibiting JUN, AMPK/p38 MAPK, PI3K, and TGF-β/Smad pathways. tanshinone, glycyrrhizin, and chickpea pigment A are mainly known for inhibiting the TGF-β/Smad signalling pathway, NF-κB phosphorylation and inflammation-related factors, and all three reduced collagen I and collagen III production. Mangiferin and chrysin inhibited myocardial fibrosis by inhibiting the MAPK cascade and TGF-β/Smad signalling pathways, respectively. Single herbs represented by Dan Shen, Tie Pi Shi Hu, Huang Jing, Huang Qi, and Chinese herbal medicine combinations represented by Compound Danshen Dripping Pill, Qiliqiangxin, Buyang Huanwu decoction, Qi Shen Yi Qi pill, and Gualou Xiebai decoction, also play an equally important role in the inhibition of myocardial fibrosis. Created in BioRender. Yan W (2025) https://BioRender.com/xf62e49.

Table 1

Table 1. Mechanisms by which natural medicines and active ingredients modulate inflammatory responses.

5 Discussion

Inflammatory responses can not only activate multiple inflammatory cells, inflammatory factors, and inflammatory pathways, but also have profound effects on myocardial fibrosis through pathways such as NLRP3 inflammatory vesicles. Therefore, controlling the inflammatory response has become an effective strategy to prevention and cure myocardial fibrosis. In this context, natural medicine and active ingredients of Chinese medicine play a role in promoting angiogenesis and improving myocardial metabolism in CVD by virtue of their multi-target and multi-pathway therapeutic advantages, and their therapeutic efficacy is precise and safe, so they have great advantages and development prospects in the treatment of CVD. Studies have shown that a variety of modern drugs have anti-myocardial fibrosis effects. While natural medicine and active ingredients target the complex molecular mechanisms of myocardial fibrosis, they can act on a variety of cytokines and signaling molecule networks to play a role.

This review comprehensively explains the role of inflammation in the development of myocardial fibrosis from the perspective of inflammation, from the perspective of inflammatory cells, inflammatory factors and inflammatory pathways, etc. This review not only focuses on the single effects of the active ingredients of natural medicine, but also covers the combined effects of single-ingredient traditional Chinese medicine and Chinese medicine compound, providing a comprehensive perspective for clinical and basic research.

The limitation of the review is that there are still significant pharmacological and translational medicine bottlenecks in the current research of natural medicines against myocardial fibrosis. Most TCM active ingredients face serious safety challenges, including dose dependence, hepatotoxicity, electrolyte disorders and risk of drug-drug interactions, e.g., glycyrrhizic acid causes pseudoaldosteronism, curcumin causes elevated liver enzymes when used in high doses, and mangiferin may enhance the toxicity of statins. And its oral bioavailability is generally low, blood concentration is difficult to maintain an effective therapeutic window, such as tanshinone oral absorption rate is low and the peak blood concentration and antifibrotic half of the effective amount of a 10-fold difference. Besides, the experimental drug models in the article are inherently different from human disease: the streptozotocin (STZ)-induced T1DM model of diabetic cardiomyopathy fails to mimic the metabolic profile of clinical T2DM, and there are huge differences between supraphysiologic doses (e.g., 500 mg/kg of curcumin) in animal experiments and tolerated doses in humans. As a review, it cites few clinical studies, and many of the agents discussed still lack long-term toxicity assessments. Further investigations are needed into their potential toxicities and drug–drug interactions.

Additionally, the complexity of the study and the diversity of natural medicine components also bring challenges: ① the complexity of the components of Chinese medicine compound preparations, and the ratio of drugs and the quality of medication will affect the efficacy of treatments, the study is more difficult, so at this stage, although the study has been carried out gradually from the active ingredient to the single-flavored drugs, and then to the Chinese medicine compound, it is still difficult to comprehensively explain all of the mechanisms of its action. ② The preventive effect of natural medicine and active ingredients in the treatment of myocardial fibrosis has to be further studied in clinical experiments and research. ③ Technology continues to progress, research continues to innovate, the come out of new technologies may bring great breakthroughs in the physiological study of myocardial fibrosis, the future of the relevant research still need to be integrated with more cutting-edge, to keep up with the latest research progress, to ensure that the study of the real-time.

In the future, we will focus on exploring the mechanism of natural medicine ingredients inducing cells to produce endogenous protective substances, and investigate in depth how reducing inflammatory response protective effect against myocardial fibrosis. In order to provide data support for the prevention and treatment of myocardial fibrosis by natural medicine and active ingredients, and to provide broader ideas for the development and use of drugs for myocardial fibrosis. Promote the research results translated into clinical use rapidly and provide valuable guidance for the clinical treatment of anti-myocardial fibrosis.

Author contributions

CS: Data curation, Formal analysis, Writing – original draft. CR: Data curation, Formal analysis, Writing – original draft. QC: Data curation, Formal analysis, Writing – original draft. YW: Methodology, Visualization, Writing – original draft. RL: Methodology, Visualization, Writing – original draft. YZ: Methodology, Visualization, Writing – original draft. SY: Writing – original draft. CW: Methodology, Visualization, Writing – original draft. YL: Funding acquisition, Supervision, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. Angelica and Astragalus extract anti-radiation myocardial fibrosis pharmacological material basis and mechanism research (2021jyjbgs-03). National Natural Science Foundation of China (82374279).

Acknowledgments

We thank Yingdong Li for the critical reading of the manuscript. Figures 1–5 were created by Biorender (www.biorender.com), for which we are grateful.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. (2023) 147(8):e93–621. doi: 10.1161/cir.0000000000001123

PubMed Abstract | Crossref Full Text | Google Scholar

2. Frangogiannis NG. Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Asp Med. (2019) 65:70–99. doi: 10.1016/j.mam.2018.07.001

PubMed Abstract | Crossref Full Text | Google Scholar

3. Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. (2021) 117(6):1450–88. doi: 10.1093/cvr/cvaa324

PubMed Abstract | Crossref Full Text | Google Scholar

4. Gyöngyösi M, Winkler J, Ramos I, Do QT, Firat H, McDonald K, et al. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail. (2017) 19(2):177–91. doi: 10.1002/ejhf.696

PubMed Abstract | Crossref Full Text | Google Scholar

5. Kalogeropoulos AP, Georgiopoulou VV, Butler J. From risk factors to structural heart disease: the role of inflammation. Heart Fail Clin. (2012) 8(1):113–23. doi: 10.1016/j.hfc.2011.08.002

PubMed Abstract | Crossref Full Text | Google Scholar

6. Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. (2016) 119(1):91–112. doi: 10.1161/circresaha.116.303577

PubMed Abstract | Crossref Full Text | Google Scholar

7. Ren Z, Zhang Z, Ling L, Liu X, Wang X. Drugs for treating myocardial fibrosis. Front Pharmacol. (2023) 14:1221881. doi: 10.3389/fphar.2023.1221881

PubMed Abstract | Crossref Full Text | Google Scholar

8. van der Pol A, van Gilst WH, Voors AA, van der Meer P. Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail. (2019) 21(4):425–35. doi: 10.1002/ejhf.1320

PubMed Abstract | Crossref Full Text | Google Scholar

9. He L, He T, Farrar S, Ji L, Liu T, Ma X. Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen Species. Cell Physiol Biochem. (2017) 44(2):532–53. doi: 10.1159/000485089

PubMed Abstract | Crossref Full Text | Google Scholar

10. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. (2014) 94(3):909–50. doi: 10.1152/physrev.00026.2013

PubMed Abstract | Crossref Full Text | Google Scholar

11. Lozhkin A, Vendrov AE, Ramos-Mondragón R, Canugovi C, Stevenson MD, Herron TJ, et al. Mitochondrial oxidative stress contributes to diastolic dysfunction through impaired mitochondrial dynamics. Redox Biol. (2022) 57:102474. doi: 10.1016/j.redox.2022.102474

PubMed Abstract | Crossref Full Text | Google Scholar

12. Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mo Life Sci. (2014) 71(4):549–74. doi: 10.1007/s00018-013-1349-6

PubMed Abstract | Crossref Full Text | Google Scholar

13. Jobling MF, Mott JD, Finnegan MT, Jurukovski V, Jurukovski V, Erickson AC, Walian PJ, et al. Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat Res. (2006) 166(6):839–48. doi: 10.1667/RR0695.1

PubMed Abstract | Crossref Full Text | Google Scholar

14. Cheng TH, Cheng PY, Shih NL, Chen IB, Wang DL, Chen JJ. Involvement of reactive oxygen species in angiotensin II-induced endothelin-1 gene expression in rat cardiac fibroblasts. J Am Coll Cardiol. (2003) 42(10):1845–54. doi: 10.1016/j.jacc.2003.06.010

PubMed Abstract | Crossref Full Text | Google Scholar

15. Siwik DA, Colucci WS. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev. (2004) 9(1):43–51. doi: 10.1023/b:Hrev.0000011393.40674.13

PubMed Abstract | Crossref Full Text | Google Scholar

16. Ohtsu H, Frank GD, Utsunomiya H, Eguchi S. Redox-dependent protein kinase regulation by angiotensin II: mechanistic insights and its pathophysiology. Antioxid Redox Signaling. (2005) 7(9–10):1315–26. doi: 10.1089/ars.2005.7.1315

PubMed Abstract | Crossref Full Text | Google Scholar

17. Wijesurendra RS, Casadei B. Mechanisms of atrial fibrillation. Heart. (2019) 105(24):1860–7. doi: 10.1136/heartjnl-2018-314267

PubMed Abstract | Crossref Full Text | Google Scholar

18. Jalife J, Kaur K. Atrial remodeling, fibrosis, and atrial fibrillation. Trends Cardiovasc Med. (2015) 25(6):475–84. doi: 10.1016/j.tcm.2014.12.015

PubMed Abstract | Crossref Full Text | Google Scholar

19. Cao W, Shi P, Ge JJ. miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1/STAT3 pathway. BMC Cardiovasc Disord. (2017) 17(1):88. doi: 10.1186/s12872-017-0520-7

PubMed Abstract | Crossref Full Text | Google Scholar

20. Gutierrez A, Van Wagoner DR. Oxidant and inflammatory mechanisms and targeted therapy in atrial fibrillation: an update. J Cardiovasc Pharmacol. (2015) 66(6):523–9. doi: 10.1097/fjc.0000000000000313

PubMed Abstract | Crossref Full Text | Google Scholar

21. Liu X, Zhang W, Luo J, Shi W, Zhang X, Li Z, et al. TRIM21 deficiency protects against atrial inflammation and remodeling post myocardial infarction by attenuating oxidative stress. Redox Biol. (2023) 62:102679. doi: 10.1016/j.redox.2023.102679

PubMed Abstract | Crossref Full Text | Google Scholar

22. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. (1993) 75(5):843–54. doi: 10.1016/0092-8674(93)90529-y

PubMed Abstract | Crossref Full Text | Google Scholar

23. Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol. (2014) 51(4):759–74. doi: 10.1177/0300985813502820

PubMed Abstract | Crossref Full Text | Google Scholar

24. Vickers KC, Rye KA, Tabet F. MicroRNAs in the onset and development of cardiovascular disease. Clin Sci (Lond). (2014) 126(3):183–94. doi: 10.1042/cs20130203

PubMed Abstract | Crossref Full Text | Google Scholar

25. Zhao Y, Du D, Chen S, Chen Z, Zhao J. New insights into the functions of MicroRNAs in cardiac fibrosis: from mechanisms to therapeutic strategies. Genes (Basel). (2022) 13(8). doi: 10.3390/genes13081390

PubMed Abstract | Crossref Full Text | Google Scholar

26. Surina S, Fontanella RA, Scisciola L, Marfella R, Paolisso G, Barbieri M. miR-21 in human cardiomyopathies. Front Cardiovasc Med. (2021) 8:767064. doi: 10.3389/fcvm.2021.767064

PubMed Abstract | Crossref Full Text | Google Scholar

27. He X, Zhang K, Gao X, Li L, Tan H, Chen J, et al. Rapid atrial pacing induces myocardial fibrosis by down-regulating Smad7 via microRNA-21 in rabbit. Heart Vessels. (2016) 31(10):1696–708. doi: 10.1007/s00380-016-0808-z

PubMed Abstract | Crossref Full Text | Google Scholar

28. Li D, Mao C, Zhou E, You J, Gao E, Han Z, et al. MicroRNA-21 mediates a positive feedback on angiotensin II-induced myofibroblast transformation. J Inflamm Res. (2020) 13:1007–20. doi: 10.2147/jir.S285714

PubMed Abstract | Crossref Full Text | Google Scholar

29. Liang H, Zhang C, Ban T, Liu Y, Mei L, Piao X, et al. A novel reciprocal loop between microRNA-21 and TGFβRIII is involved in cardiac fibrosis. Int J Biochem Cell Biol. (2012) 44(12):2152–60. doi: 10.1016/j.biocel.2012.08.019

PubMed Abstract | Crossref Full Text | Google Scholar

30. Townley-Tilson WH, Callis TE, Wang D. MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol. (2010) 42(8):1252–5. doi: 10.1016/j.biocel.2009.03.002

PubMed Abstract | Crossref Full Text | Google Scholar

31. Li N, Zhou H, Tang Q. miR-133: a suppressor of cardiac remodeling? Front Pharmacol. (2018) 9:903. doi: 10.3389/fphar.2018.00903

PubMed Abstract | Crossref Full Text | Google Scholar

32. Ma CX, Wei ZR, Sun T, Yang MH, Sun YQ, Kai KL, et al. Circ-sh3rf3/GATA-4/miR-29a regulatory axis in fibroblast-myofibroblast differentiation and myocardial fibrosis. Cell Mol Life Sci. (2023) 80(2):50. doi: 10.1007/s00018-023-04699-7

PubMed Abstract | Crossref Full Text | Google Scholar

33. Xiao L, He H, Ma L, Da M, Cheng S, Duan Y, et al. Effects of miR-29a and miR-101a expression on myocardial interstitial collagen generation after aerobic exercise in myocardial-infarcted rats. Arch Med Res. (2017) 48(1):27–34. doi: 10.1016/j.arcmed.2017.01.006

PubMed Abstract | Crossref Full Text | Google Scholar

34. Rubiś P, Totoń-Żurańska J, Wiśniowska-Śmiałek S, Holcman K, Kołton-Wróż M, Wołkow P, et al. Relations between circulating microRNAs (miR-21, miR-26, miR-29, miR-30 and miR-133a), extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy. Int J Cardiol. (2017) 231:201–6. doi: 10.1016/j.ijcard.2016.11.279

PubMed Abstract | Crossref Full Text | Google Scholar

35. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. (2009) 104(2):170–8. doi: 10.1161/circresaha.108.182535

PubMed Abstract | Crossref Full Text | Google Scholar

36. Li J, Salvador AM, Li G, Valkov N, Ziegler O, Yeri A, et al. Mir-30d regulates cardiac remodeling by intracellular and paracrine signaling. Circ Res. (2021) 128(1):e1–23. doi: 10.1161/circresaha.120.317244

PubMed Abstract | Crossref Full Text | Google Scholar

37. Barwari T, Joshi A, Mayr M. MicroRNAs in cardiovascular disease. J Am Coll Cardiol. (2016) 68(23):2577–84. doi: 10.1016/j.jacc.2016.09.945

PubMed Abstract | Crossref Full Text | Google Scholar

38. Feng Y, Huang W, Wani M, Yu X, Ashraf M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. PLoS One. (2014) 9(2):e88685. doi: 10.1371/journal.pone.0088685

PubMed Abstract | Crossref Full Text | Google Scholar

39. Hong Y, Cao H, Wang Q, Ye J, Sui L, Feng J, et al. MiR-22 may suppress fibrogenesis by targeting TGFβR I in cardiac fibroblasts. Cell Physiol Biochem. (2016) 40(6):1345–53. doi: 10.1159/000453187

PubMed Abstract | Crossref Full Text | Google Scholar

40. Li B, Liang C, Lv Y, Tan Y, Chen W. MiR-22 inhibits myocardial fibrosis in rats with myocardial infarction by targeting PTEN/akt/mTOR signaling pathway. Cell Mol Biol (Noisy-le-Grand). (2024) 70(1):28–33. doi: 10.14715/cmb/2024.70.1.4

PubMed Abstract | Crossref Full Text | Google Scholar

41. Zhang BF, Jiang H, Chen J, Hu Q, Yang S, Liu XP, et al. LncRNA H19 ameliorates myocardial infarction-induced myocardial injury and maladaptive cardiac remodelling by regulating KDM3A. J Cell Mol Med. (2020) 24(1):1099–115. doi: 10.1111/jcmm.14846

PubMed Abstract | Crossref Full Text | Google Scholar

42. Huang Y, Qi Y, Du JQ, Zhang DF. MicroRNA-34a regulates cardiac fibrosis after myocardial infarction by targeting Smad4. Expert Opin Ther Targets. (2014) 18(12):1355–65. doi: 10.1517/14728222.2014.961424

PubMed Abstract | Crossref Full Text | Google Scholar

43. Sun Y, Ren J, Wu WZ. Effect of MiR-34a on hypertension-induced hypertrophic cardiomyopathy in rats via the TGF-β1/smads signaling pathway. Minerva Med. (2021) 112(3):405–6. doi: 10.23736/s0026-4806.19.06192-5

PubMed Abstract | Crossref Full Text | Google Scholar

44. Wang J, Zhang S, Li X, Gong M. LncRNA SNHG7 promotes cardiac remodeling by upregulating ROCK1 via sponging miR-34–5p. Aging. (2020) 12(11):10441–56. doi: 10.18632/aging.103269

PubMed Abstract | Crossref Full Text | Google Scholar

45. Zhang C, Zhang Y, Zhu H, Hu J, Xie Z. MiR-34a/miR-93 target c-ski to modulate the proliferaton of rat cardiac fibroblasts and extracellular matrix deposition in vivo and in vitro. Cell Signal. (2018) 46:145–53. doi: 10.1016/j.cellsig.2018.03.005

PubMed Abstract | Crossref Full Text | Google Scholar

46. Qiao G, Xia D, Cheng Z, Zhang G. Mir-132 in atrial fibrillation directly targets connective tissue growth factor. Mol Med Rep. (2017) 16(4):4143–50. doi: 10.3892/mmr.2017.7045

PubMed Abstract | Crossref Full Text | Google Scholar

47. Wang G, Wang R, Ruan Z, Liu L, Li Y, Zhu L. MicroRNA-132 attenuated cardiac fibrosis in myocardial infarction-induced heart failure rats. Biosci Rep. (2020) 40(9). doi: 10.1042/bsr20201696

PubMed Abstract | Crossref Full Text | Google Scholar

48. Xu K, Chen C, Wu Y, Wu M, Lin L. Advances in miR-132-based biomarker and therapeutic potential in the cardiovascular system. Front Pharmacol. (2021) 12:751487. doi: 10.3389/fphar.2021.751487

PubMed Abstract | Crossref Full Text | Google Scholar

49. Nairz M, Weiss G. Iron in infection and immunity. Mol Asp Med. (2020) 75:100864. doi: 10.1016/j.mam.2020.100864

PubMed Abstract | Crossref Full Text | Google Scholar

50. Li S, Zhang X. Iron in cardiovascular disease: challenges and potentials. Front Cardiovasc Med. (2021) 8:707138. doi: 10.3389/fcvm.2021.707138

PubMed Abstract | Crossref Full Text | Google Scholar

51. Ravingerová T, Kindernay L, Barteková M, Ferko M, Adameová A, Zohdi V, et al. The molecular mechanisms of iron metabolism and its role in cardiac dysfunction and cardioprotection. Int J Mol Sci. (2020) 21(21). doi: 10.3390/ijms21217889

PubMed Abstract | Crossref Full Text | Google Scholar

52. Chen Y, Li X, Wang S, Miao R, Zhong J. Targeting iron metabolism and ferroptosis as novel therapeutic approaches in cardiovascular diseases. Nutrients. (2023) 15(3). doi: 10.3390/nu15030591

PubMed Abstract | Crossref Full Text | Google Scholar

53. Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, et al. Ferroptosis: past, present and future. Cell Death Dis. (2020) 11(2):88. doi: 10.1038/s41419-020-2298-2

PubMed Abstract | Crossref Full Text | Google Scholar

54. Shojaie L, Iorga A, Dara L. Cell death in liver diseases: a review. Int J Mol Sci. (2020) 21(24). doi: 10.3390/ijms21249682

PubMed Abstract | Crossref Full Text | Google Scholar

55. Mohr ME, Li S, Trouten AM, Stairley RA, Roddy PL, Liu C, et al. Cardiomyocyte-fibroblast interaction regulates ferroptosis and fibrosis after myocardial injury. iScience. (2024) 27(3):109219. doi: 10.1016/j.isci.2024.109219

PubMed Abstract | Crossref Full Text | Google Scholar

56. Lin LC, Liu ZY, Yang JJ, Zhao JY, Tao H. Lipid metabolism reprogramming in cardiac fibrosis. Trends Endocrinol Metab. (2024) 35(2):164–75. doi: 10.1016/j.tem.2023.10.004

PubMed Abstract | Crossref Full Text | Google Scholar

57. Du X, Dong R, Wu Y, Ni B. Physiological effects of ferroptosis on organ fibrosis. Oxid Med Cell Longevity. (2022) 2022:5295434. doi: 10.1155/2022/5295434

PubMed Abstract | Crossref Full Text | Google Scholar

58. Linkermann A, Stockwell BR, Krautwald S, Anders HJ. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol. (2014) 14(11):759–67. doi: 10.1038/nri3743

PubMed Abstract | Crossref Full Text | Google Scholar

59. Venugopal H, Hanna A, Humeres C, Frangogiannis NG. Properties and functions of fibroblasts and myofibroblasts in myocardial infarction. Cells. (2022) 11(9). doi: 10.3390/cells11091386

PubMed Abstract | Crossref Full Text | Google Scholar

60. Sampaio AF, Silva M, Dornas WC, Costa DC, Silva ME, Dos Santos RC, et al. Iron toxicity mediated by oxidative stress enhances tissue damage in an animal model of diabetes. Biometals. (2014) 27(2):349–61. doi: 10.1007/s10534-014-9717-8

PubMed Abstract | Crossref Full Text | Google Scholar

61. Zhao Y, Pan B, Lv X, Chen C, Li K, Wang Y, et al. Ferroptosis: roles and molecular mechanisms in diabetic cardiomyopathy. Front Endocrinol (Lausanne). (2023) 14:1140644. doi: 10.3389/fendo.2023.1140644

PubMed Abstract | Crossref Full Text | Google Scholar

62. Tadokoro T, Ikeda M, Ide T, Deguchi H, Ikeda S, Okabe K, et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight. (2023) 8(6). doi: 10.1172/jci.insight.169756

PubMed Abstract | Crossref Full Text | Google Scholar

63. Liu LK, Ouyang W, Zhao X, Su Sh F, Yang Y, Ding WJ, et al. Pathogenesis and prevention of radiation-induced myocardial fibrosis. Asian Pac J Cancer Prev. (2017) 18(3):583–7. doi: 10.22034/apjcp.2017.18.3.583

PubMed Abstract | Crossref Full Text | Google Scholar

64. Klein D, Schmetter A, Imsak R, Wirsdörfer F, Unger K, Jastrow H, et al. Therapy with multipotent mesenchymal stromal cells protects lungs from radiation-induced injury and reduces the risk of lung metastasis. Antioxid Redox Signaling. (2016) 24(2):53–69. doi: 10.1089/ars.2014.6183

PubMed Abstract | Crossref Full Text | Google Scholar

65. Seemann I, Gabriels K, Visser NL, Hoving S, te Poele JA, Pol JF, et al. Irradiation induced modest changes in murine cardiac function despite progressive structural damage to the myocardium and microvasculature. Radiother Oncol. (2012) 103(2):143–50. doi: 10.1016/j.radonc.2011.10.011

PubMed Abstract | Crossref Full Text | Google Scholar

66. Venkatesulu BP, Mahadevan LS, Aliru ML, Yang X, Bodd MH, Singh PK, et al. Radiation-Induced endothelial vascular injury: a review of possible mechanisms. JACC Basic Transl Sci. (2018) 3(4):563–72. doi: 10.1016/j.jacbts.2018.01.014

PubMed Abstract | Crossref Full Text | Google Scholar

67. Farhood B, Ashrafizadeh M, Khodamoradi E, Hoseini-Ghahfarokhi M, Afrashi S, Musa AE, et al. Targeting of cellular redox metabolism for mitigation of radiation injury. Life Sci. (2020) 250:117570. doi: 10.1016/j.lfs.2020.117570

PubMed Abstract | Crossref Full Text | Google Scholar

68. Mortezaee K, Goradel NH, Amini P, Shabeeb D, Musa AE, Najafi M, et al. NADPH oxidase as a target for modulation of radiation response; implications to carcinogenesis and radiotherapy. Curr Mol Pharmacol. (2019) 12(1):50–60. doi: 10.2174/1874467211666181010154709

PubMed Abstract | Crossref Full Text | Google Scholar

69. Bent R, Moll L, Grabbe S, Bros M. Interleukin-1 Beta-A friend or foe in malignancies? Int J Mol Sci. (2018) 19(8). doi: 10.3390/ijms19082155

PubMed Abstract | Crossref Full Text | Google Scholar

70. Haubner F, Ohmann E, Pohl F, Prantl L, Strutz J, Gassner HG. Effects of radiation on the expression of adhesion molecules and cytokines in a static model of human dermal microvascular endothelial cells. Clin Hemorheol Microcirc. (2013) 54(4):371–9. doi: 10.3233/ch-2012-1626

PubMed Abstract | Crossref Full Text | Google Scholar

71. Chaudhry MA, Omaruddin RA, Brumbaugh CD, Tariq MA, Pourmand N. Identification of radiation-induced microRNA transcriptome by next-generation massively parallel sequencing. J Radiat Res. (2013) 54(5):808–22. doi: 10.1093/jrr/rrt014

PubMed Abstract | Crossref Full Text | Google Scholar

72. Yusuf SW, Sami S, Daher IN. Radiation-induced heart disease: a clinical update. Cardiol Res Pract. (2011) 2011:317659. doi: 10.4061/2011/317659

PubMed Abstract | Crossref Full Text | Google Scholar

73. Suthahar N, Meijers WC, Silljé HHW, de Boer RA. From inflammation to fibrosis-molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities. Curr Heart Fail Rep. (2017) 14(4):235–50. doi: 10.1007/s11897-017-0343-y

PubMed Abstract | Crossref Full Text | Google Scholar

74. Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, Brower GL. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension. (2009) 53(6):1041–7. doi: 10.1161/hypertensionaha.108.123158

PubMed Abstract | Crossref Full Text | Google Scholar

75. Levick SP, Meléndez GC, Plante E, McLarty JL, Brower GL, Janicki JS. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res. (2011) 89(1):12–9. doi: 10.1093/cvr/cvq272

PubMed Abstract | Crossref Full Text | Google Scholar

76. Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity. (2014) 40(1):91–104. doi: 10.1016/j.immuni.2013.11.019

PubMed Abstract | Crossref Full Text | Google Scholar

77. Kim Y, Nurakhayev S, Nurkesh A, Zharkinbekov Z, Saparov A. Macrophage polarization in cardiac tissue repair following myocardial infarction. Int J Mol Sci. (2021) 22(5). doi: 10.3390/ijms22052715

PubMed Abstract | Crossref Full Text | Google Scholar

78. Chen G, Jiang H, Yao Y, Tao Z, Chen W, Huang F, et al. Macrophage, a potential targeted therapeutic immune cell for cardiomyopathy. Front Cell Dev Biol. (2022) 10:908790. doi: 10.3389/fcell.2022.908790

PubMed Abstract | Crossref Full Text | Google Scholar

79. Saradna A, Do DC, Kumar S, Fu QL, Gao P. Macrophage polarization and allergic asthma. Transl Res. (2018) 191:1–14. doi: 10.1016/j.trsl.2017.09.002

PubMed Abstract | Crossref Full Text | Google Scholar

80. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis. (2010) 30(3):245–57. doi: 10.1055/s-0030-1255354

PubMed Abstract | Crossref Full Text | Google Scholar

81. Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. (2016) 44(3):450–62. doi: 10.1016/j.immuni.2016.02.015

PubMed Abstract | Crossref Full Text | Google Scholar

82. Ren LL, Li XJ, Duan TT, Li ZH, Yang JZ, Zhang YM, et al. Transforming growth factor-β signaling: from tissue fibrosis to therapeutic opportunities. Chem-Biol Interact. (2023) 369:110289. doi: 10.1016/j.cbi.2022.110289

PubMed Abstract | Crossref Full Text | Google Scholar

83. Lafuse WP, Wozniak DJ, Rajaram MVS. Role of cardiac macrophages on cardiac inflammation, fibrosis and tissue repair. Cells. (2020) 10(1). doi: 10.3390/cells10010051

PubMed Abstract | Crossref Full Text | Google Scholar

84. Falkenham A, de Antueno R, Rosin N, Betsch D, Lee TD, Duncan R, et al. Nonclassical resident macrophages are important determinants in the development of myocardial fibrosis. Am J Pathol. (2015) 185(4):927–42. doi: 10.1016/j.ajpath.2014.11.027

PubMed Abstract | Crossref Full Text | Google Scholar

85. Hofmann U, Knorr S, Vogel B, Weirather J, Frey A, Ertl G, et al. Interleukin-13 deficiency aggravates healing and remodeling in male mice after experimental myocardial infarction. Circ Heart Fail. (2014) 7(5):822–30. doi: 10.1161/circheartfailure.113.001020

PubMed Abstract | Crossref Full Text | Google Scholar

86. Kondo H, Takahashi N, Gotoh K, Fukui A, Saito S, Aoki K, et al. Splenectomy exacerbates atrial inflammatory fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats: possible role of spleen-derived interleukin-10. Heart Rhythm. (2016) 13(1):241–50. doi: 10.1016/j.hrthm.2015.07.001

PubMed Abstract | Crossref Full Text | Google Scholar

87. Varricchi G, Marone G, Kovanen PT. Cardiac mast cells: underappreciated immune cells in cardiovascular homeostasis and disease. Trends Immunol. (2020) 41(8):734–46. doi: 10.1016/j.it.2020.06.006

PubMed Abstract | Crossref Full Text | Google Scholar

88. Poto R, Marone G, Galli SJ, Varricchi G. Mast cells: a novel therapeutic avenue for cardiovascular diseases? Cardiovasc Res. (2024) 120(7):681–98. doi: 10.1093/cvr/cvae066

PubMed Abstract | Crossref Full Text | Google Scholar

89. Frangogiannis NG, Lindsey ML, Michael LH, Youker KA, Bressler RB, Mendoza LH, et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation. (1998) 98(7):699–710. doi: 10.1161/01.cir.98.7.699

PubMed Abstract | Crossref Full Text | Google Scholar

90. Shiota N, Rysä J, Kovanen PT, Ruskoaho H, Kokkonen JO, Lindstedt KA. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens. (2003) 21(10):1935–44. doi: 10.1097/00004872-200310000-00022

PubMed Abstract | Crossref Full Text | Google Scholar

91. Zhang W, Chancey AL, Tzeng HP, Zhou Z, Lavine KJ, Gao F, et al. The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation. (2011) 124(19):2106–16. doi: 10.1161/circulationaha.111.052399

PubMed Abstract | Crossref Full Text | Google Scholar

92. Hatamochi A, Fujiwara K, Ueki H. Effects of histamine on collagen synthesis by cultured fibroblasts derived from Guinea pig skin. Arch Dermatol Res. (1985) 277(1):60–4. doi: 10.1007/bf00406482

PubMed Abstract | Crossref Full Text | Google Scholar

93. Jordana M, Befus AD, Newhouse MT, Bienenstock J, Gauldie J. Effect of histamine on proliferation of normal human adult lung fibroblasts. Thorax. (1988) 43(7):552–8. doi: 10.1136/thx.43.7.552

PubMed Abstract | Crossref Full Text | Google Scholar

94. McLarty JL, Meléndez GC, Brower GL, Janicki JS, Levick SP. Tryptase/protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts. Hypertension. (2011) 58(2):264–70. doi: 10.1161/hypertensionaha.111.169417

PubMed Abstract | Crossref Full Text | Google Scholar

95. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. (1993) 91(4):1269–81. doi: 10.1172/jci116325

PubMed Abstract | Crossref Full Text | Google Scholar

96. Zhao XY, Zhao LY, Zheng QS, Su JL, Guan H, Shang FJ, et al. Chymase induces profibrotic response via transforming growth factor-beta 1/smad activation in rat cardiac fibroblasts. Mol Cell Biochem. (2008) 310(1–2):159–66. doi: 10.1007/s11010-007-9676-2

PubMed Abstract | Crossref Full Text | Google Scholar

97. Fang KC, Raymond WW, Blount JL, Caughey GH. Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bonds of the catalytic domain. J Biol Chem. (1997) 272(41):25628–35. doi: 10.1074/jbc.272.41.25628

PubMed Abstract | Crossref Full Text | Google Scholar

98. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. (2003) 107(20):2555–8. doi: 10.1161/01.Cir.0000074041.81728.79

PubMed Abstract | Crossref Full Text | Google Scholar

99. Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J Pharmacol Exp Ther. (2011) 339(1):143–51. doi: 10.1124/jpet.111.179697

PubMed Abstract | Crossref Full Text | Google Scholar

100. Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol. (2020) 17(7):387–401. doi: 10.1038/s41569-020-0352-5

PubMed Abstract | Crossref Full Text | Google Scholar

101. Panduro M, Benoist C, Mathis D. T(reg) cells limit IFN-γ production to control macrophage accrual and phenotype during skeletal muscle regeneration. Proc Natl Acad Sci U S A. (2018) 115(11):E2585–93. doi: 10.1073/pnas.1800618115

PubMed Abstract | Crossref Full Text | Google Scholar

102. Ulloa L, Doody J, Massagué J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature. (1999) 397(6721):710–3. doi: 10.1038/17826

PubMed Abstract | Crossref Full Text | Google Scholar

103. Nevers T, Salvador AM, Grodecki-Pena A, Knapp A, Velázquez F, Aronovitz M, et al. Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circ Heart Fail. (2015) 8(4):776–87. doi: 10.1161/circheartfailure.115.002225

PubMed Abstract | Crossref Full Text | Google Scholar

104. Bradshaw AD, DeLeon-Pennell KY. T-cell regulation of fibroblasts and cardiac fibrosis. Matrix Biol. (2020) 91–92:167–75. doi: 10.1016/j.matbio.2020.04.001

Crossref Full Text | Google Scholar

105. Maier E, Duschl A, Horejs-Hoeck J. STAT6-dependent and -independent mechanisms in Th2 polarization. Eur J Immunol. (2012) 42(11):2827–33. doi: 10.1002/eji.201242433

PubMed Abstract | Crossref Full Text | Google Scholar

106. Cortez DM, Feldman MD, Mummidi S, Valente AJ, Steffensen B, Vincenti M, et al. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta, NF-kappaB, and AP-1 activation. Am J Physiol Heart Circ Physiol. (2007) 293(6):H3356–65. doi: 10.1152/ajpheart.00928.2007

PubMed Abstract | Crossref Full Text | Google Scholar

107. Feng W, Li W, Liu W, Wang F, Li Y, Yan W. IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol. (2009) 87(3):212–8. doi: 10.1016/j.yexmp.2009.06.001

PubMed Abstract | Crossref Full Text | Google Scholar

108. Bermea K, Bhalodia A, Huff A, Rousseau S, Adamo L. The role of B cells in cardiomyopathy and heart failure. Curr Cardiol Rep. (2022) 24(8):935–46. doi: 10.1007/s11886-022-01722-4

PubMed Abstract | Crossref Full Text | Google Scholar

109. Porsch F, Mallat Z, Binder CJ. Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies. Cardiovasc Res. (2021) 117(13):2544–62. doi: 10.1093/cvr/cvab285

PubMed Abstract | Crossref Full Text | Google Scholar

110. Yu M, Wen S, Wang M, Liang W, Li HH, Long Q, et al. TNF-α-secreting B cells contribute to myocardial fibrosis in dilated cardiomyopathy. J Clin Immunol. (2013) 33(5):1002–8. doi: 10.1007/s10875-013-9889-y

PubMed Abstract | Crossref Full Text | Google Scholar

111. García-Rivas G, Castillo EC, Gonzalez-Gil AM, Maravillas-Montero JL, Brunck M, Torres-Quintanilla A, et al. The role of B cells in heart failure and implications for future immunomodulatory treatment strategies. ESC Heart Fail. (2020) 7(4):1387–99. doi: 10.1002/ehf2.12744

PubMed Abstract | Crossref Full Text | Google Scholar

112. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res. (2011) 108(9):1133–45. doi: 10.1161/circresaha.110.226936

PubMed Abstract | Crossref Full Text | Google Scholar

113. Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guérin C, et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med. (2013) 19(10):1273–80. doi: 10.1038/nm.3284

PubMed Abstract | Crossref Full Text | Google Scholar

114. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. (2000) 50(3):184–95. doi: 10.1002/1097-0029(20000801)50:3%3C184::Aid-jemt2%3E3.0.Co;2-h

PubMed Abstract | Crossref Full Text | Google Scholar

115. Shen Y, Yan SY. [Activator protein-1 mRNA expression, cell proliferation and collagen synthesis induced by tumor necrosis factor-alpha in cardiac fibroblasts from rats and the effect of qiangxin decoction]. Zhong Xi Yi Jie He Xue Bao. (2008) 6(9):946–51. doi: 10.3736/jcim20080914

PubMed Abstract | Crossref Full Text | Google Scholar

116. Venkatachalam K, Venkatesan B, Valente AJ, Melby PC, Nandish S, Reusch JE, et al. WISP1, A pro-mitogenic, pro-survival factor, mediates tumor necrosis factor-alpha (TNF-alpha)-stimulated cardiac fibroblast proliferation but inhibits TNF-alpha-induced cardiomyocyte death. J Biol Chem. (2009) 284(21):14414–27. doi: 10.1074/jbc.M809757200

PubMed Abstract | Crossref Full Text | Google Scholar

117. Tsutamoto T, Wada A, Matsumoto T, Maeda K, Mabuchi N, Hayashi M, et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol. (2001) 37(8):2086–92. doi: 10.1016/s0735-1097(01)01299-2

PubMed Abstract | Crossref Full Text | Google Scholar

118. Peng J, Gurantz D, Tran V, Cowling RT, Greenberg BH. Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circ Res. (2002) 91(12):1119–26. doi: 10.1161/01.res.0000047090.08299.d5

PubMed Abstract | Crossref Full Text | Google Scholar

119. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A. (2000) 97(23):12746–51. doi: 10.1073/pnas.97.23.12746

PubMed Abstract | Crossref Full Text | Google Scholar

120. Sack M. Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factor-alpha therapy in heart disease. Pharmacol Ther. (2002) 94(1–2):123–35. doi: 10.1016/s0163-7258(02)00176-6

PubMed Abstract | Crossref Full Text | Google Scholar

121. Zhang M, Lei R, Wang L, Jiang Y, Zhou X, Wang Y. KLF4 regulates FAM3A to promotes angiotensin II-induced proliferation and migration of vascular smooth muscle cells through the PI3 K/AKT signaling pathway. Peptides. (2025) 187:171379. doi: 10.1016/j.peptides.2025.171379

PubMed Abstract | Crossref Full Text | Google Scholar

122. Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. (2021) 128(11):1728–46. doi: 10.1161/circresaha.121.319077

PubMed Abstract | Crossref Full Text | Google Scholar

123. González GE, Rhaleb NE, D’Ambrosio MA, Nakagawa P, Liu Y, Leung P, et al. Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension. J Hypertens. (2015) 33(1):144–52. doi: 10.1097/hjh.0000000000000358

PubMed Abstract | Crossref Full Text | Google Scholar

124. Aliyu M, Zohora FT, Anka AU, Ali K, Maleknia S, Saffarioun M, et al. Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach. Int Immunopharmacol. (2022) 111:109130. doi: 10.1016/j.intimp.2022.109130

PubMed Abstract | Crossref Full Text | Google Scholar

125. Fang G, Li Y, Yuan J, Cao W, Song S, Chen L, et al. Cadherin-11-Interleukin-6 signaling between cardiac fibroblast and cardiomyocyte promotes ventricular remodeling in a mouse pressure overload-induced heart failure model. Int J Mol Sci. (2023) 24(7). doi: 10.3390/ijms24076549

PubMed Abstract | Crossref Full Text | Google Scholar

126. Kumar S, Wang G, Zheng N, Cheng W, Ouyang K, Lin H, et al. HIMF (hypoxia-induced mitogenic factor)-IL (interleukin)-6 signaling mediates cardiomyocyte-fibroblast crosstalk to promote cardiac hypertrophy and fibrosis. Hypertension. (2019) 73(5):1058–70. doi: 10.1161/hypertensionaha.118.12267

PubMed Abstract | Crossref Full Text | Google Scholar

127. Datta R, Bansal T, Rana S, Datta K, Datta Chaudhuri R, Chawla-Sarkar M, et al. Myocyte-derived Hsp90 modulates collagen upregulation via biphasic activation of STAT-3 in fibroblasts during cardiac hypertrophy. Mol Cell Biol. (2017) 37(6). doi: 10.1128/mcb.00611-16

PubMed Abstract | Crossref Full Text | Google Scholar

128. Zhang Y, Wang JH, Zhang YY, Wang YZ, Wang J, Zhao Y, et al. Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGFβ1 and miR-29 pathways. Sci Rep. (2016) 6:23010. doi: 10.1038/srep23010

PubMed Abstract | Crossref Full Text | Google Scholar

129. Rathinam VA, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol. (2012) 13(4):333–42. doi: 10.1038/ni.2237

PubMed Abstract | Crossref Full Text | Google Scholar

130. Wang Y, Wu Y, Chen J, Zhao S, Li H. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology. (2013) 126(1):1–11. doi: 10.1159/000351179

PubMed Abstract | Crossref Full Text | Google Scholar

131. Artlett CM. The mechanism and regulation of the NLRP3 inflammasome during fibrosis. Biomolecules. (2022) 12(5). doi: 10.3390/biom12050634

PubMed Abstract | Crossref Full Text | Google Scholar

132. Lee HT, Lee JG, Na M, Kay EP. FGF-2 induced by interleukin-1 beta through the action of phosphatidylinositol 3-kinase mediates endothelial mesenchymal transformation in corneal endothelial cells. J Biol Chem. (2004) 279(31):32325–32. doi: 10.1074/jbc.M405208200

PubMed Abstract | Crossref Full Text | Google Scholar

133. Lee JG, Kay EP. NF-κB is the transcription factor for FGF-2 that causes endothelial mesenchymal transformation in cornea. Invest Ophthalmol Visual Sci. (2012) 53(3):1530–8. doi: 10.1167/iovs.11-9102

PubMed Abstract | Crossref Full Text | Google Scholar

134. Jackson AO, Zhang J, Jiang Z, Yin K. Endothelial-to-mesenchymal transition: a novel therapeutic target for cardiovascular diseases. Trends Cardiovasc Med. (2017) 27(6):383–93. doi: 10.1016/j.tcm.2017.03.003

PubMed Abstract | Crossref Full Text | Google Scholar

135. Zhang H, Hui H, Li Z, Pan J, Jiang X, Wei T, et al. Pigment epithelium-derived factor attenuates myocardial fibrosis via inhibiting endothelial-to-mesenchymal transition in rats with acute myocardial infarction. Sci Rep. (2017) 7:41932. doi: 10.1038/srep41932

PubMed Abstract | Crossref Full Text | Google Scholar

136. Martínez-Martínez E, Calvier L, Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni LV, et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension. (2015) 66(4):767–75. doi: 10.1161/hypertensionaha.115.05876

PubMed Abstract | Crossref Full Text | Google Scholar

137. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. (2009) 11(9):811–7. doi: 10.1093/eurjhf/hfp097

PubMed Abstract | Crossref Full Text | Google Scholar

138. Liu YH, D’Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol. (2009) 296(2):H404–12. doi: 10.1152/ajpheart.00747.2008

PubMed Abstract | Crossref Full Text | Google Scholar

139. Garner OB, Baum LG. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochem Soc Trans. (2008) 36(Pt 6):1472–7. doi: 10.1042/bst0361472

PubMed Abstract | Crossref Full Text | Google Scholar

140. Nabi IR, Shankar J, Dennis JW. The galectin lattice at a glance. J Cell Sci. (2015) 128(13):2213–9. doi: 10.1242/jcs.151159

PubMed Abstract | Crossref Full Text | Google Scholar

141. Mathy NL, Scheuer W, Lanzendörfer M, Honold K, Ambrosius D, Norley S, et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology. (2000) 100(1):63–9. doi: 10.1046/j.1365-2567.2000.00997.x

PubMed Abstract | Crossref Full Text | Google Scholar

142. Tamaki S, Mano T, Sakata Y, Ohtani T, Takeda Y, Kamimura D, et al. Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction. PLoS One. (2013) 8(7):e68893. doi: 10.1371/journal.pone.0068893

PubMed Abstract | Crossref Full Text | Google Scholar

143. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. (2009) 9(8):556–67. doi: 10.1038/nri2586

PubMed Abstract | Crossref Full Text | Google Scholar

144. Yan X, Shichita T, Katsumata Y, Matsuhashi T, Ito H, Ito K, et al. Deleterious effect of the IL-23/IL-17A axis and γδT cells on left ventricular remodeling after myocardial infarction. J Am Heart Assoc. (2012) 1(5):e004408. doi: 10.1161/jaha.112.004408

PubMed Abstract | Crossref Full Text | Google Scholar

145. Valente AJ, Yoshida T, Gardner JD, Somanna N, Delafontaine P, Chandrasekar B. Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1/DUSP-1. Cell Signal. (2012) 24(2):560–8. doi: 10.1016/j.cellsig.2011.10.010

PubMed Abstract | Crossref Full Text | Google Scholar

146. Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev Immunol. (2015) 33:417–43. doi: 10.1146/annurev-immunol-032414-112134

PubMed Abstract | Crossref Full Text | Google Scholar

147. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. (2002) 16(6):779–90. doi: 10.1016/s1074-7613(02)00324-2

PubMed Abstract | Crossref Full Text | Google Scholar

148. Ma X, Meng Q, Gong S, Shi S, Liang X, Lin F, et al. IL-27 promotes cardiac fibroblast activation and aggravates cardiac remodeling post myocardial infarction. Heliyon. (2023) 9(6):e17099. doi: 10.1016/j.heliyon.2023.e17099

PubMed Abstract | Crossref Full Text | Google Scholar

149. Choi P, Reiser H. IL-4: role in disease and regulation of production. Clin Exp Immunol. (1998) 113(3):317–9. doi: 10.1046/j.1365-2249.1998.00690.x

PubMed Abstract | Crossref Full Text | Google Scholar

150. Ricci M. IL-4: a key cytokine in atopy. Clin Exp Allergy. (1994) 24(9):801–12. doi: 10.1111/j.1365-2222.1994.tb01803.x

PubMed Abstract | Crossref Full Text | Google Scholar

151. Kanellakis P, Ditiatkovski M, Kostolias G, Bobik A. A pro-fibrotic role for interleukin-4 in cardiac pressure overload. Cardiovasc Res. (2012) 95(1):77–85. doi: 10.1093/cvr/cvs142

PubMed Abstract | Crossref Full Text | Google Scholar

152. Bischoff SC, Sellge G, Lorentz A, Sebald W, Raab R, Manns MP. IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci U S A. (1999) 96(14):8080–5. doi: 10.1073/pnas.96.14.8080

PubMed Abstract | Crossref Full Text | Google Scholar

153. Hara M, Ono K, Hwang MW, Iwasaki A, Okada M, Nakatani K, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. (2002) 195(3):375–81. doi: 10.1084/jem.20002036

PubMed Abstract | Crossref Full Text | Google Scholar

154. Peng H, Sarwar Z, Yang XP, Peterson EL, Xu J, Janic B, et al. Profibrotic role for interleukin-4 in cardiac remodeling and dysfunction. Hypertension. (2015) 66(3):582–9. doi: 10.1161/hypertensionaha.115.05627

PubMed Abstract | Crossref Full Text | Google Scholar

155. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science. (2011) 332(6035):1284–8. doi: 10.1126/science.1204351

PubMed Abstract | Crossref Full Text | Google Scholar

156. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. (2010) 32(5):593–604. doi: 10.1016/j.immuni.2010.05.007

PubMed Abstract | Crossref Full Text | Google Scholar

157. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. (2011) 29:71–109. doi: 10.1146/annurev-immunol-031210-101312

PubMed Abstract | Crossref Full Text | Google Scholar

158. Krishnamurthy P, Thal M, Verma S, Hoxha E, Lambers E, Ramirez V, et al. Interleukin-10 deficiency impairs bone marrow-derived endothelial progenitor cell survival and function in ischemic myocardium. Circ Res. (2011) 109(11):1280–9. doi: 10.1161/circresaha.111.248369

PubMed Abstract | Crossref Full Text | Google Scholar

159. Hulsmans M, Sager HB, Roh JD, Valero-Muñoz M, Houstis NE, Iwamoto Y, et al. Cardiac macrophages promote diastolic dysfunction. J Exp Med. (2018) 215(2):423–40. doi: 10.1084/jem.20171274

PubMed Abstract | Crossref Full Text | Google Scholar

160. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel “alarmin”? PLoS One. (2008) 3(10):e3331. doi: 10.1371/journal.pone.0003331

PubMed Abstract | Crossref Full Text | Google Scholar

161. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. (2007) 117(6):1538–49. doi: 10.1172/jci30634

PubMed Abstract | Crossref Full Text | Google Scholar

162. Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33/ST2 axis in organ fibrosis. Front Immunol. (2018) 9:2432. doi: 10.3389/fimmu.2018.02432

PubMed Abstract | Crossref Full Text | Google Scholar

163. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. (2005) 23(5):479–90. doi: 10.1016/j.immuni.2005.09.015

PubMed Abstract | Crossref Full Text | Google Scholar

164. Pascual-Figal DA, Januzzi JL. The biology of ST2: the international ST2 consensus panel. Am J Cardiol. (2015) 115(7 Suppl):3b–7. doi: 10.1016/j.amjcard.2015.01.034

PubMed Abstract | Crossref Full Text | Google Scholar

165. Tseng CCS, Huibers MMH, van Kuik J, de Weger RA, Vink A, de Jonge N. The interleukin-33/ST2 pathway is expressed in the failing human heart and associated with pro-fibrotic remodeling of the myocardium. J Cardiovasc Transl Res. (2018) 11(1):15–21. doi: 10.1007/s12265-017-9775-8

PubMed Abstract | Crossref Full Text | Google Scholar

166. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harbor Perspect Biol. (2009) 1(6):a001651. doi: 10.1101/cshperspect.a001651

PubMed Abstract | Crossref Full Text | Google Scholar

167. Wang J, Shen W, Zhang JY, Jia CH, Xie ML. Stevioside attenuates isoproterenol-induced mouse myocardial fibrosis through inhibition of the myocardial NF-κB/TGF-β1/smad signaling pathway. Food Funct. (2019) 10(2):1179–90. doi: 10.1039/c8fo01663a

PubMed Abstract | Crossref Full Text | Google Scholar

168. Timmers L, van Keulen JK, Hoefer IE, Meijs MF, van Middelaar B, den Ouden K, et al. Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction. Circ Res. (2009) 104(5):699–706. doi: 10.1161/circresaha.108.189746

PubMed Abstract | Crossref Full Text | Google Scholar

169. Zhou Y, Ji J, Ji L, Wang L, Hong F. Respiratory exposure to nano-TiO(2) induces pulmonary toxicity in mice involving reactive free radical-activated TGF-β/smad/p38MAPK/wnt pathways. J Biomed Mater Res Part A. (2019) 107(11):2567–75. doi: 10.1002/jbm.a.36762

Crossref Full Text | Google Scholar

170. Bredeson S, Papaconstantinou J, Deford JH, Kechichian T, Syed TA, Saade GR, et al. HMGB1 promotes a p38MAPK associated non-infectious inflammatory response pathway in human fetal membranes. PLoS One. (2014) 9(12):e113799. doi: 10.1371/journal.pone.0113799

PubMed Abstract | Crossref Full Text | Google Scholar

171. Xue Q, Wang X, Wang P, Zhang K, Liu Q. Role of p38MAPK in apoptosis and autophagy responses to photodynamic therapy with chlorin e6. Photodiagnosis Photodyn Ther. (2015) 12(1):84–91. doi: 10.1016/j.pdpdt.2014.12.001

PubMed Abstract | Crossref Full Text | Google Scholar

172. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. (1993) 122(1):103–11. doi: 10.1083/jcb.122.1.103

PubMed Abstract | Crossref Full Text | Google Scholar

173. Molkentin JD, Bugg D, Ghearing N, Dorn LE, Kim P, Sargent MA, et al. Fibroblast-specific genetic manipulation of p38 mitogen-activated protein kinase in vivo reveals its central regulatory role in fibrosis. Circulation. (2017) 136(6):549–61. doi: 10.1161/circulationaha.116.026238

PubMed Abstract | Crossref Full Text | Google Scholar

174. Turner NA, Blythe NM. Cardiac fibroblast p38 MAPK: a critical regulator of myocardial remodeling. J Cardiovasc Dev Dis. (2019) 6(3). doi: 10.3390/jcdd6030027

PubMed Abstract | Crossref Full Text | Google Scholar

175. Chen L, Yang T, Lu DW, Zhao H, Feng YL, Chen H, et al. Central role of dysregulation of TGF-β/smad in CKD progression and potential targets of its treatment. Biomed Pharmacother. (2018) 101:670–81. doi: 10.1016/j.biopha.2018.02.090

PubMed Abstract | Crossref Full Text | Google Scholar

176. Hu HH, Chen DQ, Wang YN, Feng YL, Cao G, Vaziri ND, et al. New insights into TGF-β/smad signaling in tissue fibrosis. Chem Biol Interact. (2018) 292:76–83. doi: 10.1016/j.cbi.2018.07.008

PubMed Abstract | Crossref Full Text | Google Scholar

177. Liu J, Lu J, Zhang L, Liu Y, Zhang Y, Gao Y, et al. The combination of exercise and metformin inhibits TGF-β1/smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB-mediated inflammatory response. Biomed Pharmacother. (2023) 157:114080. doi: 10.1016/j.biopha.2022.114080

PubMed Abstract | Crossref Full Text | Google Scholar

178. Meng XM, Nikolic-Paterson DJ, Lan HY. Inflammatory processes in renal fibrosis. Nat Rev Nephrol. (2014) 10(9):493–503. doi: 10.1038/nrneph.2014.114

PubMed Abstract | Crossref Full Text | Google Scholar

179. Khalil H, Kanisicak O, Prasad V, Correll RN, Fu X, Schips T, et al. Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis. J Clin Invest. (2017) 127(10):3770–83. doi: 10.1172/jci94753

PubMed Abstract | Crossref Full Text | Google Scholar

180. Yue Y, Meng K, Pu Y, Zhang X. Transforming growth factor beta (TGF-β) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res Clin Pract. (2017) 133:124–30. doi: 10.1016/j.diabres.2017.08.018

PubMed Abstract | Crossref Full Text | Google Scholar

181. Ferreira RR, de Souza EM, de Oliveira FL, Ferrão PM, Gomes LH, Mendonça-Lima L, et al. Proteins involved on TGF-β pathway are up-regulated during the acute phase of experimental chagas disease. Immunobiology. (2016) 221(5):587–94. doi: 10.1016/j.imbio.2016.01.009

PubMed Abstract | Crossref Full Text | Google Scholar

182. Li ZL, Shi Y, Ding Y, Ran Y, Le G. Dietary oxidized tyrosine (O-tyr) stimulates TGF-β1-induced extracellular matrix production via the JNK/p38 signaling pathway in rat kidneys. Amino Acids. (2017) 49(2):241–60. doi: 10.1007/s00726-016-2353-6

PubMed Abstract | Crossref Full Text | Google Scholar

183. Wojciechowski MC, Mahmutovic L, Shu DY, Lovicu FJ. ERK1/2 signaling is required for the initiation but not progression of TGFβ-induced lens epithelial to mesenchymal transition (EMT). Exp Eye Res. (2017) 159:98–113. doi: 10.1016/j.exer.2017.03.012

PubMed Abstract | Crossref Full Text | Google Scholar

184. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. (2004) 117(Pt 8):1281–3. doi: 10.1242/jcs.00963

PubMed Abstract | Crossref Full Text | Google Scholar

185. Kim BK, Tran HY, Shin EJ, Lee C, Chung YH, Jeong JH, et al. IL-6 attenuates trimethyltin-induced cognitive dysfunction via activation of JAK2/STAT3, M1 mAChR and ERK signaling network. Cell Signal. (2013) 25(6):1348–60. doi: 10.1016/j.cellsig.2013.02.017

PubMed Abstract | Crossref Full Text | Google Scholar

186. Singh R, Kaundal RK, Zhao B, Bouchareb R, Lebeche D. Resistin induces cardiac fibroblast-myofibroblast differentiation through JAK/STAT3 and JNK/c-Jun signaling. Pharmacol Res. (2021) 167:105414. doi: 10.1016/j.phrs.2020.105414

PubMed Abstract | Crossref Full Text | Google Scholar

187. Chakraborty D, Šumová B, Mallano T, Chen CW, Distler A, Bergmann C, et al. Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun. (2017) 8(1):1130. doi: 10.1038/s41467-017-01236-6

PubMed Abstract | Crossref Full Text | Google Scholar

188. Han J, Ye S, Zou C, Chen T, Wang J, Li J, et al. Angiotensin II causes biphasic STAT3 activation through TLR4 to initiate cardiac remodeling. Hypertension. (2018) 72(6):1301–11. doi: 10.1161/hypertensionaha.118.11860

PubMed Abstract | Crossref Full Text | Google Scholar

189. Green JP, Yu S, Martín-Sánchez F, Pelegrin P, Lopez-Castejon G, Lawrence CB, et al. Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming. Proc Natl Acad Sci U S A. (2018) 115(40):E9371–80. doi: 10.1073/pnas.1812744115

PubMed Abstract | Crossref Full Text | Google Scholar

190. Zhang WJ, Chen SJ, Zhou SC, Wu SZ, Wang H. Inflammasomes and fibrosis. Front Immunol. (2021) 12:643149. doi: 10.3389/fimmu.2021.643149

PubMed Abstract | Crossref Full Text | Google Scholar

191. Liu D, Zeng X, Li X, Mehta JL, Wang X. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Res Cardiol. (2018) 113(1):5. doi: 10.1007/s00395-017-0663-9

PubMed Abstract | Crossref Full Text | Google Scholar

192. Zhang X, Qu H, Yang T, Kong X, Zhou H. Regulation and functions of NLRP3 inflammasome in cardiac fibrosis: current knowledge and clinical significance. Biomed Pharmacother. (2021) 143:112219. doi: 10.1016/j.biopha.2021.112219

PubMed Abstract | Crossref Full Text | Google Scholar

193. Grebe A, Hoss F, Latz E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ Res. (2018) 122(12):1722–40. doi: 10.1161/circresaha.118.311362

PubMed Abstract | Crossref Full Text | Google Scholar

194. Pan XC, Liu Y, Cen YY, Xiong YL, Li JM, Ding YY, et al. Dual role of triptolide in interrupting the NLRP3 inflammasome pathway to attenuate cardiac fibrosis. Int J Mol Sci. (2019) 20(2). doi: 10.3390/ijms20020360

PubMed Abstract | Crossref Full Text | Google Scholar

195. Yan R, Sun Y, Yang Y, Zhang R, Jiang Y, Meng Y. Mitochondria and NLRP3 inflammasome in cardiac hypertrophy. Mol Cell Biochem. (2024) 479(7):1571–82. doi: 10.1007/s11010-023-04812-1

PubMed Abstract | Crossref Full Text | Google Scholar

196. Liu H, Liu A, Shi C, Li B. Curcumin suppresses transforming growth factor-β1-induced cardiac fibroblast differentiation via inhibition of smad-2 and p38 MAPK signaling pathways. Exp Ther Med. (2016) 11(3):998–1004. doi: 10.3892/etm.2016.2969

PubMed Abstract | Crossref Full Text | Google Scholar

197. Yu W, Wu J, Cai F, Xiang J, Zha W, Fan D, et al. Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PLoS One. (2012) 7(12):e52013. doi: 10.1371/journal.pone.0052013

PubMed Abstract | Crossref Full Text | Google Scholar

198. Patel SS, Acharya A, Ray RS, Agrawal R, Raghuwanshi R, Jain P. Cellular and molecular mechanisms of curcumin in prevention and treatment of disease. Crit Rev Food Sci Nutr. (2020) 60(6):887–939. doi: 10.1080/10408398.2018.1552244

PubMed Abstract | Crossref Full Text | Google Scholar

199. Zeng C, Zhong P, Zhao Y, Kanchana K, Zhang Y, Khan ZA, et al. Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-κB both in vitro and in vivo. J Mol Cell Cardiol. (2015) 79:1–12. doi: 10.1016/j.yjmcc.2014.10.002

PubMed Abstract | Crossref Full Text | Google Scholar

200. Cao Q, Zhang J, Gao L, Zhang Y, Dai M, Bao M. Dickkopf-3 upregulation mediates the cardioprotective effects of curcumin on chronic heart failure. Mol Med Rep. (2018) 17(5):7249–57. doi: 10.3892/mmr.2018.8783

PubMed Abstract | Crossref Full Text | Google Scholar

201. Guo S, Meng XW, Yang XS, Liu XF, Ou-Yang CH, Liu C. Curcumin administration suppresses collagen synthesis in the hearts of rats with experimental diabetes. Acta Pharmacol Sin. (2018) 39(2):195–204. doi: 10.1038/aps.2017.92

PubMed Abstract | Crossref Full Text | Google Scholar

202. Abdelsamia EM, Khaleel SA, Balah A, Abdel Baky NA. Curcumin augments the cardioprotective effect of metformin in an experimental model of type I diabetes mellitus; impact of Nrf2/HO-1 and JAK/STAT pathways. Biomed Pharmacother. (2019) 109:2136–44. doi: 10.1016/j.biopha.2018.11.064

PubMed Abstract | Crossref Full Text | Google Scholar

203. Han X, Yang Y, Zhang M, Li L, Xue Y, Jia Q, et al. Liquiritin protects against cardiac fibrosis after myocardial infarction by inhibiting CCL5 expression and the NF-κB signaling pathway. Drug Des Devel Ther. (2022) 16:4111–25. doi: 10.2147/dddt.S386805

PubMed Abstract | Crossref Full Text | Google Scholar

204. Zhang Y, Zhang L, Zhang Y, Xu JJ, Sun LL, Li SZ. The protective role of liquiritin in high fructose-induced myocardial fibrosis via inhibiting NF-κB and MAPK signaling pathway. Biomed Pharmacother. (2016) 84:1337–49. doi: 10.1016/j.biopha.2016.10.036

PubMed Abstract | Crossref Full Text | Google Scholar

205. Cheng J, Ren C, Cheng R, Li Y, Liu P, Wang W, et al. Mangiferin ameliorates cardiac fibrosis in D-galactose-induced aging rats by inhibiting TGF-β/p38/MK2 signaling pathway. Korean J Physiol Pharmacol. (2021) 25(2):131–7. doi: 10.4196/kjpp.2021.25.2.131

PubMed Abstract | Crossref Full Text | Google Scholar

206. Song J, Meng Y, Wang M, Li L, Liu Z, Zheng K, et al. Mangiferin activates Nrf2 to attenuate cardiac fibrosis via redistributing glutaminolysis-derived glutamate. Pharmacol Res. (2020) 157:104845. doi: 10.1016/j.phrs.2020.104845

PubMed Abstract | Crossref Full Text | Google Scholar

207. Zheng D, Hou J, Xiao Y, Zhao Z, Chen L. Cardioprotective effect of mangiferin on left ventricular remodeling in rats. Pharmacology. (2012) 90(1–2):78–87. doi: 10.1159/000339450

PubMed Abstract | Crossref Full Text | Google Scholar

208. Suchal K, Malik S, Gamad N, Malhotra RK, Goyal SN, Ojha S, et al. Mangiferin protect myocardial insults through modulation of MAPK/TGF-β pathways. Eur J Pharmacol. (2016) 776:34–43. doi: 10.1016/j.ejphar.2016.02.055

PubMed Abstract | Crossref Full Text | Google Scholar

209. Arozal W, Suyatna FD, Juniantito V, Rosdiana DS, Amurugam S, Aulia R, et al. The effects of mangiferin (Mangifera indica L) in doxorubicin-induced cardiotoxicity in rats. Drug Res. (2015) 65(11):574–80. doi: 10.1055/s-0034-1394457

PubMed Abstract | Crossref Full Text | Google Scholar

210. Yang Y, Li J, Rao T, Fang Z, Zhang J. The role and mechanism of hyperoside against myocardial infarction in mice by regulating autophagy via NLRP1 inflammation pathway. J Ethnopharmacol. (2021) 276:114187. doi: 10.1016/j.jep.2021.114187

PubMed Abstract | Crossref Full Text | Google Scholar

211. Zong J, Zhang H, Li FF, Liang K, Liu JL, Xu LH, et al. NLRP1 promotes TGF-β1-induced myofibroblast differentiation in neonatal rat cardiac fibroblasts. J Mol Histol. (2018) 49(5):509–18. doi: 10.1007/s10735-018-9789-9

PubMed Abstract | Crossref Full Text | Google Scholar

212. Wang X, Liu Y, Xiao L, Li L, Zhao X, Yang L, et al. Hyperoside protects against pressure overload-induced cardiac remodeling via the AKT signaling pathway. Cell Physiol Biochem. (2018) 51(2):827–41. doi: 10.1159/000495368

PubMed Abstract | Crossref Full Text | Google Scholar

213. Feng Z, Zhang N, Bai J, Lin QY, Xie Y, Xia YL. Biochanin A inhibits cardiac hypertrophy and fibrosis in vivo and in vitro. Biomed Pharmacother. (2024) 170:116002. doi: 10.1016/j.biopha.2023.116002

PubMed Abstract | Crossref Full Text | Google Scholar

214. Sharma M, Singh TU, Rana A, Kumar T, Gari M, Mani P, et al. Biochanin-A alleviates fibrosis and inflammation in cardiac injury in mice. J Biochem Mol Toxicol. (2023) 37(7):e23360. doi: 10.1002/jbt.23360

PubMed Abstract | Crossref Full Text | Google Scholar

215. Wang P, Zhou S, Xu L, Lu Y, Yuan X, Zhang H, et al. Hydrogen peroxide-mediated oxidative stress and collagen synthesis in cardiac fibroblasts: blockade by tanshinone IIA. J Ethnopharmacol. (2013) 145(1):152–61. doi: 10.1016/j.jep.2012.10.044

PubMed Abstract | Crossref Full Text | Google Scholar

216. Li W, Zhang Y, Xing C, Zhang M. Tanshinone IIA represses inflammatory response and reduces radiculopathic pain by inhibiting IRAK-1 and NF-κB/p38/JNK signaling. Int Immunopharmacol. (2015) 28(1):382–9. doi: 10.1016/j.intimp.2015.06.032

PubMed Abstract | Crossref Full Text | Google Scholar

217. Bi Z, Wang Y, Zhang W. A comprehensive review of tanshinone IIA and its derivatives in fibrosis treatment. Biomed Pharmacother. (2021) 137:111404. doi: 10.1016/j.biopha.2021.111404

PubMed Abstract | Crossref Full Text | Google Scholar

218. Subedi L, Gaire BP. Tanshinone IIA: a phytochemical as a promising drug candidate for neurodegenerative diseases. Pharmacol Res. (2021) 169:105661. doi: 10.1016/j.phrs.2021.105661

PubMed Abstract | Crossref Full Text | Google Scholar

219. Jiang Z, Gao W, Huang L. Tanshinones, critical pharmacological components in Salvia miltiorrhiza. Front Pharmacol. (2019) 10:202. doi: 10.3389/fphar.2019.00202

PubMed Abstract | Crossref Full Text | Google Scholar

220. Zhou ZY, Zhao WR, Zhang J, Chen XL, Tang JY. Sodium tanshinone IIA sulfonate: a review of pharmacological activity and pharmacokinetics. Biomed Pharmacother. (2019) 118:109362. doi: 10.1016/j.biopha.2019.109362

PubMed Abstract | Crossref Full Text | Google Scholar

221. Zhan CY, Tang JH, Zhou DX, Li ZH. Effects of tanshinone IIA on the transforming growth factor β1/smad signaling pathway in rat cardiac fibroblasts. Indian J Pharmacol. (2014) 46(6):633–8. doi: 10.4103/0253-7613.144933

PubMed Abstract | Crossref Full Text | Google Scholar

222. Zhou D, Li Z, Zhang L, Zhan C. Inhibitory effect of tanshinone II A on TGF II-β1-induced cardiac fibrosis. J Huazhong Univ Sci Technol Med Sci. (2012) 32(6):829–33. doi: 10.1007/s11596-012-1042-2

PubMed Abstract | Crossref Full Text | Google Scholar

223. Chen T, Li M, Fan X, Cheng J, Wang L. Sodium tanshinone IIA sulfonate prevents angiotensin II-induced differentiation of human atrial fibroblasts into myofibroblasts. Oxid Med Cell Longevity. (2018) 2018:6712585. doi: 10.1155/2018/6712585

PubMed Abstract | Crossref Full Text | Google Scholar

224. Yang L, Zou XJ, Gao X, Chen H, Luo JL, Wang ZH, et al. Sodium tanshinone IIA sulfonate attenuates angiotensin II-induced collagen type I expression in cardiac fibroblasts in vitro. Exp Mol Med. (2009) 41(7):508–16. doi: 10.3858/emm.2009.41.7.056

PubMed Abstract | Crossref Full Text | Google Scholar

225. Gao S, Yang Z, Li D, Wang B, Zheng X, Li C, et al. Intervention of tanshinone IIA on the PGK1-PDHK1 pathway to reprogram macrophage phenotype after myocardial infarction. Cardiovasc Drugs Ther. (2023). doi: 10.1007/s10557-023-07520-6

Crossref Full Text | Google Scholar

226. Yan N, Xiao C, Wang X, Xu Z, Yang J. Tanshinone IIA from Salvia miltiorrhiza exerts anti-fibrotic effects on cardiac fibroblasts and rat heart tissues by suppressing the levels of pro-fibrotic factors: the key role of miR-618. J Food Biochem. (2022) 46(2):e14078. doi: 10.1111/jfbc.14078

PubMed Abstract | Crossref Full Text | Google Scholar

227. Zhou R, Gao J, Xiang C, Liu Z, Zhang Y, Zhang J, et al. Salvianolic acid A attenuated myocardial infarction-induced apoptosis and inflammation by activating Trx. Naunyn Schmiedebergs Arch Pharmacol. (2020) 393(6):991–1002. doi: 10.1007/s00210-019-01766-4

PubMed Abstract | Crossref Full Text | Google Scholar

228. Wu R, Zhang L, Xu H, Chen H, Zhao W, Zhou Y, et al. Salvia miltiorrhiza extract prevents the occurrence of early atherosclerosis in apoe -/- mice via TLR4/NF-kB pathway. Cardiovasc Hematol Agents Med Chem. (2023) 21(3):232–9. doi: 10.2174/1871525721666230206112134

PubMed Abstract | Crossref Full Text | Google Scholar

229. Xu L, Zeng X, Liu Y, Wu Z, Zheng X, Zhang X. Effect of dendrobium officinale polysaccharides on central nervous system disease: based on gut microbiota. Int J Biol Macromol. (2023) 240:124440. doi: 10.1016/j.ijbiomac.2023.124440

PubMed Abstract | Crossref Full Text | Google Scholar

230. Lin X, Shaw PC, Sze SC, Tong Y, Zhang Y. Dendrobium officinale polysaccharides ameliorate the abnormality of aquaporin 5, pro-inflammatory cytokines and inhibit apoptosis in the experimental sjögren’s syndrome mice. Int Immunopharmacol. (2011) 11(12):2025–32. doi: 10.1016/j.intimp.2011.08.014

PubMed Abstract | Crossref Full Text | Google Scholar

231. Lin Y, Yang T, Shen L, Zhang J, Liu L. Study on the properties of dendrobiumofficinale fermentation broth as functional raw material of cosmetics. J Cosmet Dermatol. (2022) 21(3):1216–23. doi: 10.1111/jocd.14197

PubMed Abstract | Crossref Full Text | Google Scholar

232. Cui X, Wang S, Cao H, Guo H, Li Y, Xu F, et al. A review: the bioactivities and pharmacological applications of Polygonatum sibiricum polysaccharides. Molecules. (2018) 23(5). doi: 10.3390/molecules23051170

Crossref Full Text | Google Scholar

233. Wang W, Li S, Song M. Polygonatum sibiricum polysaccharide inhibits high glucose-induced oxidative stress, inflammatory response, and apoptosis in RPE cells. J Recept Signal Transduct Res. (2022) 42(2):189–96. doi: 10.1080/10799893.2021.1883061

PubMed Abstract | Crossref Full Text | Google Scholar

234. Cai J, Zhu Y, Zuo Y, Tong Q, Zhang Z, Yang L, et al. Polygonatum sibiricum polysaccharide alleviates inflammatory cytokines and promotes glucose uptake in high-glucose- and high-insulin-induced 3T3-L1 adipocytes by promoting Nrf2 expression. Mol Med Rep. (2019) 20(4):3951–8. doi: 10.3892/mmr.2019.10626

PubMed Abstract | Crossref Full Text | Google Scholar

235. Lei S, Lu X, Yan L, Liu T, Niu Y, Yu J. Polygonatum sibiricum (Huang Jing) polysaccharide reduces diabetic cardiomyopathy through increasing cyclic guanosine monophosphate-protein kinase G signaling in diabetic mice. J Diabetes Investig. (2024) 15(7):823–34. doi: 10.1111/jdi.14192

PubMed Abstract | Crossref Full Text | Google Scholar

236. Wang S, Li G, Zhang X, Wang Y, Qiang Y, Wang B, et al. Structural characterization and antioxidant activity of Polygonatum sibiricum polysaccharides. Carbohydr Polym. (2022) 291:119524. doi: 10.1016/j.carbpol.2022.119524

PubMed Abstract | Crossref Full Text | Google Scholar

237. Jiang M, Ni J, Cao Y, Xing X, Wu Q, Fan G. Astragaloside IV attenuates myocardial ischemia-reperfusion injury from oxidative stress by regulating succinate, lysophospholipid metabolism, and ROS scavenging system. Oxid Med Cell Longevity. (2019) 2019:9137654. doi: 10.1155/2019/9137654

PubMed Abstract | Crossref Full Text | Google Scholar

238. Sun C, Zeng G, Wang T, Ren H, An H, Lian C, et al. Astragaloside IV ameliorates myocardial infarction induced apoptosis and restores cardiac function. Front Cell Dev Biol. (2021) 9:671255. doi: 10.3389/fcell.2021.671255

PubMed Abstract | Crossref Full Text | Google Scholar

239. Wei D, Xu H, Gai X, Jiang Y. Astragaloside IV alleviates myocardial ischemia-reperfusion injury in rats through regulating PI3K/AKT/GSK-3β signaling pathways. Acta Cirurgica Brasileira. (2019) 34(7):e201900708. doi: 10.1590/s0102-865020190070000008

PubMed Abstract | Crossref Full Text | Google Scholar

240. Du J, Xie J, Zhang Z, Tsujikawa H, Fusco D, Silverman D, et al. TRPM7-mediated Ca2+signals confer fibrogenesis in human atrial fibrillation. Circ Res. (2010) 106(5):992–1003. doi: 10.1161/circresaha.109.206771

PubMed Abstract | Crossref Full Text | Google Scholar

241. Liang Y, Zou J, Zhang X, Wang Y, Tai J, Guo D, et al. The relationship between compound danshen dripping pills with isosorbide mononitrate in the treatment of elderly patients with unstable angina pectoris. Evid Based Complement Altern Med. (2018) 2018:3429151. doi: 10.1155/2018/3429151

PubMed Abstract | Crossref Full Text | Google Scholar

242. Luo J, Xu H, Chen K. Systematic review of compound danshen dropping pill: a Chinese patent medicine for acute myocardial infarction. Evid Based Complement Altern Med. (2013) 2013:808076. doi: 10.1155/2013/808076

PubMed Abstract | Crossref Full Text | Google Scholar

243. Hu Y, Sun J, Wang T, Wang H, Zhao C, Wang W, et al. Compound danshen dripping pill inhibits high altitude-induced hypoxic damage by suppressing oxidative stress and inflammatory responses. Pharm Biol. (2021) 59(1):1585–93. doi: 10.1080/13880209.2021.1998139

PubMed Abstract | Crossref Full Text | Google Scholar

244. Hu YX, You HM, Ren CZ, Hu BW, Zhang LJ, Zhang YD, et al. Proangiogenesis effects of compound danshen dripping pills in zebrafish. BMC Complement Med Ther. (2022) 22(1):112. doi: 10.1186/s12906-022-03589-y

PubMed Abstract | Crossref Full Text | Google Scholar

245. Lei W, Li X, Li L, Huang M, Cao Y, Sun X, et al. Compound danshen dripping pill ameliorates post ischemic myocardial inflammation through synergistically regulating MAPK, PI3K/AKT and PPAR signaling pathways. J Ethnopharmacol. (2021) 281:114438. doi: 10.1016/j.jep.2021.114438

PubMed Abstract | Crossref Full Text | Google Scholar

246. Zhou H, Sun Y, Zhang L, Kang W, Li N, Li Y. The RhoA/ROCK pathway mediates high glucose-induced cardiomyocyte apoptosis via oxidative stress, JNK, and p38MAPK pathways. Diabetes Metab Res Rev. (2018) 34(6):e3022. doi: 10.1002/dmrr.3022

PubMed Abstract | Crossref Full Text | Google Scholar

247. Yang Y, Feng K, Yuan L, Liu Y, Zhang M, Guo K, et al. Compound danshen dripping pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient mice via multiple mechanisms. Acta Pharm Sin B. (2023) 13(3):1036–52. doi: 10.1016/j.apsb.2022.11.012

PubMed Abstract | Crossref Full Text | Google Scholar

248. Zhang Y, Zhao J, Ding R, Niu W, He Z, Liang C. Pre-treatment with compound danshen dripping pills prevents lipid infusion-induced microvascular dysfunction in mice. Pharm Biol. (2020) 58(1):701–6. doi: 10.1080/13880209.2020.1790619

PubMed Abstract | Crossref Full Text | Google Scholar

249. Li X, Zhang J, Huang J, Ma A, Yang J, Li W, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. (2013) 62(12):1065–72. doi: 10.1016/j.jacc.2013.05.035

PubMed Abstract | Crossref Full Text | Google Scholar

250. Wang J, Zhou J, Wang Y, Yang C, Fu M, Zhang J, et al. Qiliqiangxin protects against anoxic injury in cardiac microvascular endothelial cells via NRG-1/ErbB-PI3K/akt/mTOR pathway. J Cell Mol Med. (2017) 21(9):1905–14. doi: 10.1111/jcmm.13111

PubMed Abstract | Crossref Full Text | Google Scholar

251. Wang T, Hou B, Qin H, Liang J, Shi M, Song Y, et al. Qili qiangxin (QLQX) capsule as a multi-functional traditional Chinese medicine in treating chronic heart failure (CHF): a review of ingredients, molecular, cellular, and pharmacological mechanisms. Heliyon. (2023) 9(11):e21950. doi: 10.1016/j.heliyon.2023.e21950

PubMed Abstract | Crossref Full Text | Google Scholar

252. Zhou J, Jiang K, Ding X, Fu M, Wang S, Zhu L, et al. Qiliqiangxin inhibits angiotensin II-induced transdifferentiation of rat cardiac fibroblasts through suppressing interleukin-6. J Cell Mol Med. (2015) 19(5):1114–21. doi: 10.1111/jcmm.12512

PubMed Abstract | Crossref Full Text | Google Scholar

253. Lu Y, Xiang M, Xin L, Zhang Y, Wang Y, Shen Z, et al. Qiliqiangxin modulates the gut microbiota and NLRP3 inflammasome to protect against ventricular remodeling in heart failure. Front Pharmacol. (2022) 13:905424. doi: 10.3389/fphar.2022.905424

PubMed Abstract | Crossref Full Text | Google Scholar

254. Han A, Lu Y, Zheng Q, Zhang J, Zhao Y, Zhao M, et al. Qiliqiangxin attenuates cardiac remodeling via inhibition of TGF-β1/Smad3 and NF-κB signaling pathways in a rat model of myocardial infarction. Cell Physiol Biochem. (2018) 45(5):1797–806. doi: 10.1159/000487871

PubMed Abstract | Crossref Full Text | Google Scholar

255. Chen H, Lou L, Zhang D, Zhao Y, Zhao J, Li C, et al. Qiliqiangxin capsule improves cardiac function and attenuates cardiac remodeling by upregulating miR-133a after myocardial infarction in rats. Evid Based Complement Altern Med. (2019) 2019:7528214. doi: 10.1155/2019/7528214

PubMed Abstract | Crossref Full Text | Google Scholar

256. Sun X, Chen G, Xie Y, Jiang D, Han J, Chen F, et al. Qiliqiangxin improves cardiac function and attenuates cardiac remodelling in doxorubicin-induced heart failure rats. Pharm Biol. (2020) 58(1):417–26. doi: 10.1080/13880209.2020.1761403

PubMed Abstract | Crossref Full Text | Google Scholar

257. She Y, Shao L, Jiao K, Sun R, Lang T, Long H, et al. Glycosides of Buyang Huanwu decoction inhibits pyroptosis associated with cerebral ischemia-reperfusion through Nrf2-mediated antioxidant signaling pathway both in vivo and in vitro. Phytomedicine. (2023) 120:155001. doi: 10.1016/j.phymed.2023.155001

PubMed Abstract | Crossref Full Text | Google Scholar

258. Li MC, Li MZ, Lin ZY, Zhuang YM, Wang HY, Jia JT, et al. Buyang Huanwu decoction promotes neurovascular remodeling by modulating astrocyte and microglia polarization in ischemic stroke rats. J Ethnopharmacol. (2024) 323:117620. doi: 10.1016/j.jep.2023.117620

PubMed Abstract | Crossref Full Text | Google Scholar

259. Chen Y, Surinkaew S, Naud P, Qi XY, Gillis MA, Shi YF, et al. JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate. Cardiovasc Res. (2017) 113(3):310–20. doi: 10.1093/cvr/cvx004

PubMed Abstract | Crossref Full Text | Google Scholar

260. Fu X, Sun Z, Long Q, Tan W, Ding H, Liu X, et al. Glycosides from Buyang Huanwu decoction inhibit atherosclerotic inflammation via JAK/STAT signaling pathway. Phytomedicine. (2022) 105:154385. doi: 10.1016/j.phymed.2022.154385

PubMed Abstract | Crossref Full Text | Google Scholar

261. Wang T, Jiang X, Ruan Y, Zhuang J, Yin Y. Based on network pharmacology and in vitro experiments to prove the effective inhibition of myocardial fibrosis by Buyang Huanwu decoction. Bioengineered. (2022) 13(5):13767–83. doi: 10.1080/21655979.2022.2084253

PubMed Abstract | Crossref Full Text | Google Scholar

262. Zhang G, Han X, Xu T, Liu M, Chen G, Xie L, et al. Buyang Huanwu decoction suppresses cardiac inflammation and fibrosis in mice after myocardial infarction through inhibition of the TLR4 signalling pathway. J Ethnopharmacol. (2024) 320:117388. doi: 10.1016/j.jep.2023.117388

PubMed Abstract | Crossref Full Text | Google Scholar

263. Chen JR, Wei J, Wang LY, Zhu Y, Li L, Olunga MA, et al. Cardioprotection against ischemia/reperfusion injury by QiShenYiQi pill® via ameliorate of multiple mitochondrial dysfunctions. Drug Des Devel Ther. (2015) 9:3051–66. doi: 10.2147/dddt.S82146

PubMed Abstract | Crossref Full Text | Google Scholar

264. Chen YY, Li Q, Pan CS, Yan L, Fan JY, He K, et al. Qishenyiqi pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode. Sci Rep. (2015) 5:11802. doi: 10.1038/srep11802

PubMed Abstract | Crossref Full Text | Google Scholar

265. Li Z, Yu Y, Bu Y, Liu C, Jin J, Li W, et al. Qishenyiqi pills preserve endothelial barrier integrity to mitigate sepsis-induced acute lung injury by inhibiting ferroptosis. J Ethnopharmacol. (2024) 322:117610. doi: 10.1016/j.jep.2023.117610

PubMed Abstract | Crossref Full Text | Google Scholar

266. Gupta SS, Zeglinski MR, Rattan SG, Landry NM, Ghavami S, Wigle JT, et al. Inhibition of autophagy inhibits the conversion of cardiac fibroblasts to cardiac myofibroblasts. Oncotarget. (2016) 7(48):78516–31. doi: 10.18632/oncotarget.12392

PubMed Abstract | Crossref Full Text | Google Scholar

267. Lv S, Yuan P, Dong J, Lu C, Li M, Qu F, et al. Qishenyiqi pill improves the reparative myocardial fibrosis by regulating autophagy. J Cell Mol Med. (2020) 24(19):11283–93. doi: 10.1111/jcmm.15695

PubMed Abstract | Crossref Full Text | Google Scholar

268. Li M, Wang Y, Qi Z, Yuan Z, Lv S, Zheng Y, et al. Qishenyiqi dripping pill protects against myocardial ischemia/reperfusion injury via suppressing excessive autophagy and NLRP3 inflammasome based on network pharmacology and experimental pharmacology. Front Pharmacol. (2022) 13:981206. doi: 10.3389/fphar.2022.981206

PubMed Abstract | Crossref Full Text | Google Scholar

269. Zheng QN, Wei XH, Pan CS, Li Q, Liu YY, Fan JY, et al. Qishenyiqi pills(®) ameliorates ischemia/reperfusion-induced myocardial fibrosis involving RP S19-mediated TGFβ1/smads signaling pathway. Pharmacol Res. (2019) 146:104272. doi: 10.1016/j.phrs.2019.104272

PubMed Abstract | Crossref Full Text | Google Scholar

270. Li C, Wang Y, Qiu Q, Shi T, Wu Y, Han J, et al. Qishenyiqi protects ligation-induced left ventricular remodeling by attenuating inflammation and fibrosis via STAT3 and NF-κB signaling pathway. PLoS One. (2014) 9(8):e104255. doi: 10.1371/journal.pone.0104255

PubMed Abstract | Crossref Full Text | Google Scholar

271. Wang J, Lu L, Wang Y, Wu Y, Han J, Wang W, et al. Qishenyiqi dropping pill attenuates myocardial fibrosis in rats by inhibiting RAAS-mediated arachidonic acid inflammation. J Ethnopharmacol. (2015) 176:375–84. doi: 10.1016/j.jep.2015.11.023

PubMed Abstract | Crossref Full Text | Google Scholar

272. Zhang F, Duan B, Zhou Z, Han L, Huang P, Ye Y, et al. Integration of metabolomics and transcriptomics to reveal anti-chronic myocardial ischemia mechanism of Gualou Xiebai decoction. J Ethnopharmacol. (2022) 297:115530. doi: 10.1016/j.jep.2022.115530

PubMed Abstract | Crossref Full Text | Google Scholar

273. Zhang WY, Yu Y, Yan LL, Li C, Han JY, Qin ZF, et al. Discovery of cardio-protective constituents of Gualou Xiebai decoction, a classical traditional Chinese medicinal formula. Phytomedicine. (2019) 54:318–27. doi: 10.1016/j.phymed.2018.04.047

PubMed Abstract | Crossref Full Text | Google Scholar

274. Ding YF, Peng YR, Li J, Shen H, Shen MQ, Fang TH. Gualou Xiebai decoction prevents myocardial fibrosis by blocking TGF-beta/smad signalling. J Pharm Pharmacol. (2013) 65(9):1373–81. doi: 10.1111/jphp.12102

PubMed Abstract | Crossref Full Text | Google Scholar

275. Ding YF, Peng YR, Shen H, Shu L, Wei YJ. Gualou Xiebai decoction inhibits cardiac dysfunction and inflammation in cardiac fibrosis rats. BMC Complement Altern Med. (2016) 16:49. doi: 10.1186/s12906-016-1012-5

PubMed Abstract | Crossref Full Text | Google Scholar